Podcasts about freestyle libre

Sie ist Berlinerin, zweifache Mama, rebellische Pädagogin und liebevoll unbequem. Als Mama einer Tochter mit Typ-1-Diabetes kennt sie die Herausforderungen im Familienalltag aus erster Hand. Mit ihrer Erfahrung als Erzieherin, Pflegedienstleisterin und Alltagsprofi begleitet sie Mütter, die echt statt perfekt sein wollen – besonders dann, wenn das Leben mit einer Diabetes-Diagnose plötzlich alles verändert. -- [Werbung]  Die Folge wird präsentiert von FreeStyle Libre Messystem – dem derzeit kleinsten und flachsten Sensor der Welt. Nach einer Aktivierungszeit von 60 Minuten misst der Sensor jede einzelne Minute. Weitere Infos und Hinweise zum FreeStyle Libre Messsystem: https://www.freestylelibre.de/produkte/freestyle-libre-3-entdecken.html [Werbung] Show Notes Weitere Infos zu FreeStyle Libre 3https://www.freestylelibre.de/produkte/freestyle-libre-3-entdecken.html www.freestylelibre.de Erwähnte Seiten, Blogs etc. 276 – KLAFA Klassenfahrtbetreuung für Kinder mit Diabetes Typ 1 160 – Dia Engel – Die Nummer bei Diabetes Kummer Was liest Du, hast Du gelesen bzw. gehört (Hörbuch) und was kannst Du empfehlen? Ich lese gerade 3 Bücher gleichzeitig. Eher Fachliteratur als Romane. Romane hau' ich mir eher aufs Ohr, weil ich diese einfach im Auto, während meiner täglichen Tour hören kann. Tiefenheilung und Transformation von Hans TenDam Königsmörder-Chronik von Patrick Rothfuss Kontaktdaten E-Mail: jeannette-kriesel@gmx.de Website: https://www.jeannette-kriesel.de/ Telegram: https://t.me/jeannettekriesel  

In this brutally honest and hilariously relatable episode, Mike and Jack go 10 rounds comparing the two most talked-about CGMs for people with Type 1 diabetes — Dexcom One+ and Freestyle Libre 2.Mike has officially ditched Libre and gone full Dexcom… but was the switch worth it? And is Jack about to follow?We cover EVERYTHING:

In this episode of Diabetes Dialogue, co-hosts hosts Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and co-director of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center, discuss significant developments in diabetes care from May 2025, including Medtronic's restructured business model, Sequel Twiist's technological collaboration with Abbott, and Breakthrough T1D's efforts to advance early detection of type 1 diabetes (T1D) through national screening initiatives. The discussion opens with news of Medtronic's decision to spin off its diabetes division into a standalone entity, currently referred to as “New Diabetes Company.” While the final name is forthcoming, the move is intended to streamline operations and accelerate innovation within the diabetes space. The hosts highlight the company's promising technology pipeline, including the forthcoming 800 series insulin pump with full smartphone control and plans for a tubeless insulin delivery system. Both experts express optimism that the independence may foster greater agility in product development, enhance accessibility, and maintain a focus on user-centered design, including for populations with visual impairments. Next, Isaacs and Bellini examine the announcement of the Sequel Twiist partnership with Abbott to integrate continuous ketone monitoring (CKM) into a hybrid sensor, which is expected to function similarly to the FreeStyle Libre 3. This device, still in development, will provide real-time data on both glucose and ketone levels—a critical advance for people with type 1 diabetes using insulin pumps, who are at elevated risk for diabetic ketoacidosis (DKA). While excited about the potential for earlier DKA detection, Bellini emphasizes the importance of cost-effective implementation and integration with existing pump platforms. The episode concludes with coverage of Breakthrough T1D's advocacy before the US Preventive Services Task Force to support routine screening for T1D autoantibodies. The goal is to identify individuals in early stages of the disease to prevent DKA and misdiagnosis. The hosts note that despite advancements in understanding T1D progression, many patients remain undiagnosed until presenting with DKA or are mistakenly classified as having type 2 diabetes. References: Medtronic plc. Medtronic announces intent to separate Diabetes business. Medtronic News. Published May 21, 2025. Accessed June 2, 2025. https://news.medtronic.com/2025-05-21-Medtronic-announces-intent-to-separate-Diabetes-business Sequel Med Tech. Sequel Med Tech to Integrate twiist Automated Insulin Delivery (AID) System with Abbott's Future Dual Glucose-Ketone Sensor. GlobeNewswire News Room. Published May 22, 2025. Accessed June 2, 2025. https://www.globenewswire.com/news-release/2025/05/22/3086535/0/en/Sequel-Med-Tech-to-Integrate-twiist-Automated-Insulin-Delivery-AID-System-with-Abbott-s-Future-Dual-Glucose-Ketone-Sensor.html Breakthrough T1D. Breakthrough T1D Submits Application to Make Screening for Type 1 Diabetes Part of Recommended Preventive Services in the US - Breakthrough T1D. Breakthrough T1D. Published May 21, 2025. Accessed June 2, 2025. https://www.breakthrought1d.org/for-the-media/press-releases/breakthrough-t1d-submits-application-to-make-screening-for-type-1-diabetes-part-of-recommended-preventive-services-in-the-us/

In dieser Folge erleben wir, wie eine smarte KI den gesamten Morgen durchplant: vom Urin-Check über den Spiegel-Scan bis zur Zahnbürste, die Termine bucht, ohne zu fragen. Alles vernetzt, alles freundlich übergriffig – aber genau so, wie wir Zuckerjunkies es lieben: ein bisschen verrückt, aber voll auf den Punkt. -- [Werbung]  Die Folge wird präsentiert von FreeStyle Libre Messystem – dem derzeit kleinsten und flachsten Sensor der Welt. Nach einer Aktivierungszeit von 60 Minuten misst der Sensor jede einzelne Minute. Weitere Infos und Hinweise zum FreeStyle Libre Messsystem: https://www.freestylelibre.de/produkte/freestyle-libre-3-entdecken.html [Werbung] Show Notes Weitere Infos zu FreeStyle Libre 3https://www.freestylelibre.de/produkte/freestyle-libre-3-entdecken.html www.freestylelibre.de Erwähnte Seiten, Blogs etc. 156 – K'Watch und K'apsul – Die vielleicht neue CGM Uhr Revolution? 252 – Sensor misst Gewebezucker über Hautschweiß 199 – Labor auf einem Pflaster – Nerdy Talk Smarte Matratzen & Schlafüberwachung: Bryte Smart Beds bieten personalisierte Schlafanalysen und passen sich automatisch an die Bedürfnisse des Nutzers an Sleep Number integriert Gesundheitsüberwachung in Matratzen, um den Schlaf und die Gesundheit zu verbessern Intelligente Badezimmerspiegel: CareOS bietet mit dem BMirror eine Plattform, die Gesundheitsdaten analysiert und personalisierte Empfehlungen gibt Shen AI verwandelt Spiegel in persönliche Wellness-Stationen, die Vitalzeichen wie Herzfrequenz und Stress messen Smarte Zahnbürsten: Feno Smartbrush reinigt alle Zähne gleichzeitig in 20 Sekunden und liefert Gesundheitsberichte über eine App Oral-B iO Series 10 bietet KI-gestützte Coaching-Funktionen für eine optimale Mundhygiene Smarte Kleidung: Hexoskin Smart Garments überwachen kontinuierlich Herzfrequenz, Atmung und Aktivität und werden bereits in der Forschung eingesetzt HealthWatch entwickelt tragbare Lösungen zur Fernüberwachung der Gesundheit mit in Kleidung integrierten Sensoren Smarte Toiletten & Urinanalyse: U-Scan von Withings ist ein Gerät für die Urinanalyse zu Hause, das Gesundheitsdaten direkt in die Toilette integriert TrueLoo von Toi Labs ist ein KI-gestützter Toilettensitz, der Urin und Stuhl analysiert, um Gesundheitsveränderungen zu erkennen  

Was haben ein sprechender CGM, ein Präsident mit zwei Bauchspeicheldrüsen und ein verpeilter Typ beim Frühstück gemeinsam? Richtig: Typ-1-Diabetes – im Weltall! In „Per Anhalter durch den Blutzucker“ reist Arthur unfreiwillig quer durch die Galaxis, trifft schräge Rebellen und lernt, dass BE-Schätzen manchmal mehr ist als Mathematik. -- [Werbung]  Die Folge wird präsentiert von FreeStyle Libre Messystem – dem derzeit kleinsten und flachsten Sensor der Welt. Nach einer Aktivierungszeit von 60 Minuten misst der Sensor jede einzelne Minute. Weitere Infos und Hinweise zum FreeStyle Libre Messsystem: https://www.freestylelibre.de/produkte/freestyle-libre-3-entdecken.html [Werbung] Show Notes Weitere Infos zu FreeStyle Libre 3https://www.freestylelibre.de/produkte/freestyle-libre-3-entdecken.html www.freestylelibre.de Erwähnte Seiten, Blogs etc. 415 – Robinson Crusoe und die Insulinfische 412 – Adam und Eva 2.0 411 – Die 4 Reiter der Apokalypse … hatten Diabetes 409 – Gott mit Diabetes Typ 1 – Neue Schöpfungslehre 405 – Vaterunser für Diabetiker

Du träumst von Sonne, Strand und ein bisschen mehr Leichtigkeit im Umgang mit deinem Typ-1-Diabetes? Dann ist diese Folge genau dein Ding! Michelle Schmidt nimmt dich mit in ihre Idee einer begleiteten Ägyptenreise für Diabetiker*innen – mit Community, Entspannung und einer großen Portion Mut.

This week on We Are T1D, Mike and Jack unpack the reality of living with unreliable diabetes tech — from Freestyle Libre sensor failures to the emotional stress of depending on CGMs that just don't work. After five sensor fails in six weeks, Mike's had enough, and he's not holding back.Also in this episode:⚠️ How sensor failures trigger CGM anxiety (and why warm-ups now feel like betting on luck)

Tamara lebt seit 26 Jahren mit Typ‑1‑Diabetes und kennt ihre Vorsorgepflichten. Dennoch trifft sie die Nachricht hart: Auf dem OCT‑Bild (eine Art Netzhautscanner) sind Ansammlungen von Flüssigkeit zu sehen. Beide Augen sind betroffen – ein doppelter Dämpfer für die junge Mutter und Kinderbuchautorin. Ihre erste Reaktion: Fassungslosigkeit, Tränen und die Frage »Warum jetzt?«. Doch der Therapieplan steht schnell. -- [Werbung]  Die Folge wird präsentiert von FreeStyle Libre Messystem – dem derzeit kleinsten und flachsten Sensor der Welt. Nach einer Aktivierungszeit von 60 Minuten misst der Sensor jede einzelne Minute. Weitere Infos und Hinweise zum FreeStyle Libre Messsystem: https://www.freestylelibre.de/produkte/freestyle-libre-3-entdecken.html [Werbung] Show Notes Weitere Infos zu FreeStyle Libre 3https://www.freestylelibre.de/produkte/freestyle-libre-3-entdecken.html www.freestylelibre.de Erwähnte Seiten, Blogs etc. 277 – Diabetisches Makulaödem oder wenn der Zucker auf die Augen geht 320 – Voll versägt – Schnipp Schnapp Zeh ist ab

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: A new Austrailian study aims to prevent type 1, the new twiist pump will integrate with Eversnse CGM as well as Libre, diabetes deaths are down in the US, Dexcom U is looking for college athletes, and more! Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom   Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links: Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX A world-first human trial of a drug designed to treat the underlying cause of type 1 diabetes has begun in Australia. University of Queensland researcher Ranjeny Thomas said the experimental drug — dubbed ASITI-201 — was designed to retrain the immune system so it no longer attacks the insulin-producing pancreatic cells, known as beta cells. The drug, given as an injection under the skin, combines fragments of a protein found in the beta cells of people with type 1 diabetes and vitamin D to calm the immune response. She said if effective, the drug would initially be given to patients with type 1 diabetes as soon as possible after diagnosis to preserve remaining pancreatic cells and reduce the amount of insulin needed. But eventually, if screening programs can be developed to pick up people at risk of developing type 1 diabetes, it may be possible to "prevent the progression of the disease altogether". The first in-human trial of 36 participants will test the safety of the drug, but blood tests will also determine the impact of the therapy on a patient's immune system and glucose tolerance. https://www.abc.net.au/news/2025-04-29/type-1-diabetes-drug-trial-auto-immune-disease-science/105223022 XX   Diabetes deaths in the U.S. have fallen to some of the lowest rates in years, according to new preliminary figures published by the Centers for Disease Control and Prevention, reversing a surge in mortality that was seen during the COVID-19 pandemic.   There were 26.4 deaths per 100,000 people from diabetes, according to early death certificate data for the third quarter of 2024 published this month by the CDC's National Center for Health Statistics.   Death rates from diabetes peaked in 2021, according to CDC figures, at 31.1 deaths per 100,000 people for that year. Diabetes was the eighth leading cause of death in 2021. The CDC says the link between COVID-19 and diabetes may be to blame for that increase.   "Data show an increase in mortality rates for all people during the COVID-19 pandemic, and research shows that people with underlying conditions, including diabetes, are more likely to become very sick from COVID-19 and have a higher risk of hospitalization and death," Christopher Holliday, head of the CDC's Division of Diabetes Translation, told CBS News in a statement.   Holliday added that research shows the pandemic may also have made it harder for Americans to properly manage the disease, ranging from interruptions to physical activity to disruptions to routine medical care diagnosing and treating the disease.   https://www.cbsnews.com/news/diabetes-deaths-lowest-levels-years-early-cdc-figures/ XX Big news for the Eversense CGM – they have their first pump partner. Sequel Med Tech says the twist pump will integrate with Senseonics Eversense 365 continuous glucose monitor (CGM). This collaboration would make twiist the first AID system compatible with Eversense 365, the world's first and only one-year CGM. Sequel and Senseonics say they have already started their work to integrate the latest-generation, 365-day implantable sensor with twiist. They expect to make the integrated offering available in the third quarter of this year. This marks the second CGM integration for Sequel, which partnered with Abbott and its FreeStyle Libre platform earlier this year. This week we also got a peek at the packaging and delivery of the twist as the first people posted about wearing it. We'll follow up and learn more about this newest insulin pump in the us. Senseonics, meanwhile, brought the first year-long CGM to market last year, launching Eversense 365 with its global distribution partner, Ascensia Diabetes Care, in October 2024. The system also received clearance as an integrated CGM (iCGM) system, meaning it can work with compatible medical devices. Those include insulin pumps as part of automated insulin delivery systems. https://www.drugdeliverybusiness.com/sequel-senseonics-integrate-cgm-insulin-pump/ XX Medtronic has announced the U.S. Food and Drug Administration (FDA) approval for the Simplera Sync sensor for use with the MiniMed 780G system. With this approval, the MiniMed 780G system now offers more flexibility for users of the company's most advanced insulin delivery system featuring Meal Detection technology with both the Guardian 4 sensor and Simplera Sync sensor.   The Simplera Sync is a disposable, all-in-one sensor that requires no fingersticks with SmartGuard or overtape and features a simple, two-step insertion process. It is the company's newest addition to its CGM portfolio, which expands options and provides greater flexibility for users.   The MiniMed 780G system's adaptive algorithm automatically anticipates, adjusts, and corrects glucose levels every 5 minutes, 24/7 – working around the clock so users can focus on what matters. It's the only system featuring Meal Detection technology, which detects rising sugar levels and delivers more insulin as needed to help users keep glucose levels in range more often – even when users occasionally forget to dose insulin for snacks or meals or underestimate their carbs.   The system uses a “treat to target” approach and flexible glucose targets as low as 100 mg/dL, which, combined with its adaptive algorithm allows it to more closely mirror the glucose levels of someone not living with diabetes.   Real-world data of the system shows global users consistently achieve time in range above international targets of 70% when using optimal settings (active insulin time of two hours and 100 mg/dL target glucose). It is also the only system that works with the world's only infusion set that lasts up to 7 days so that users only have to change their infusion set once per week and can experience 96% fewer injections compared to multiple daily injections.   “We're committed to driving innovation that makes life easier for those living with diabetes so they can forget about their diabetes as much as possible throughout the day,” said Que Dallara, EVP and president of Medtronic Diabetes. “Our MiniMed 780G system delivers advanced diabetes technology for so many around the world, and we're excited to continue evolving this experience with expanded CGM options —including our Simplera Sync sensor, which we look forward to bringing to people living with diabetes in the U.S.”   A limited launch of the Simplera Sync sensor will begin in the U.S. in the fall of 2025. Today, the MiniMed 780G system can be used with the Guardian 4 sensor.   Like this:https://med-techinsights.com/2025/04/29/simplera-sync-sensor-for-minimed-780g-now-fda-approved/ XX Front office changes at Insulet.. The former head of Johnson & Johnson's worldwide medtech business, Ashley McEvoy will take over as president and CEO from Jim Hollingshead, who has led Insulet since 2022. In its announcement of the leadership change, Insulet said that Hollingshead and the company mutually agreed to part ways, effective immediately. McEvoy served as worldwide medtech chairman at J&J from 2018 until her departure in late 2023, the culmination of nearly 30 years at the company and several executive roles—including president of its Ethicon division and group chairman of vision and diabetes care. Since then, she has also served as a board member at Procter & Gamble. https://www.fiercebiotech.com/medtech/insulet-taps-former-jj-medtech-head-ashley-mcevoy-be-ceo XX New free mobile game launched this week to make type 1 diabetes onboarding faster easier and less overwhelming. It's called Level One.. created by Level Ex (Powered by Relevate Health), the studio behind award-winning medical games for medical professionals. Level Ex CEO Sam Glassenberg created the game after a – quote  - brutal onboarding experience when his daughter was diagnosed five years ago He says  It took a year to understand how to manage this disease. So we fixed it. We built a game that can train your brain to do it in a matter of hours." The game is launching in partnership with leading diabetes organizations Beyond Type 1 and Breakthrough T1D Play, who are integrating Level One into their outreach and educational campaigns to support newly diagnosed families worldwide. Download Level One on the App Store: https://apps.apple.com/us/app/level-one-a-diabetes-game/id6739605694 Learn more: https://playlevelone.com   https://www.prnewswire.com/news-releases/level-ex-launches-level-one-a-free-mobile-game-to-redefine-type-1-diabetes-onboarding-302440929.html XX   Collagen is widely recognized for its role in maintaining healthy skin, but its importance extends far beyond that. As the most abundant protein in the human body, collagen provides essential structure and support to nearly all tissues and organs.   Now, researchers at Carnegie Mellon's Feinberg Lab have made a major breakthrough using their novel Freeform Reversible Embedding of Suspended Hydrogels (FRESH) 3D bioprinting technique. This method enables the precise printing of soft, living cells and tissues. Leveraging this technology, the team successfully created the first-ever microphysiologic system, also known as a tissue model, constructed entirely from collagen. This advancement opens new possibilities for studying disease and engineering tissue therapies, including potential treatments for conditions like Type 1 diabetes.   Traditionally, small-scale models of human tissue, referred to as microfluidics, organ-on-chip devices, or microphysiologic systems, have been fabricated using synthetic materials such as silicone rubber or plastics. These materials were necessary due to limitations in earlier manufacturing techniques. However, because they are not biologically native, they fail to fully replicate natural tissue environments, restricting their effectiveness in biomedical research and therapeutic development.   “Now, we can build microfluidic systems in the Petri dish entirely out of collagen, cells, and other proteins, with unprecedented structural resolution and fidelity,” explained Adam Feinberg, a professor of biomedical engineering and materials science & engineering at Carnegie Mellon University. “Most importantly, these models are fully biologic, which means cells function better.”   Building Complex Tissues with FRESH Bioprinting In new research published in Science Advances, the group demonstrates the use of this FRESH bioprinting advancement, building more complex vascularized tissues out of fully biologic materials, to create a pancreatic-like tissue that could potentially be used in the future to treat Type 1 diabetes. This advancement in FRESH bioprinting builds on the team's earlier work published in Science, by improving the resolution and quality to create fluidic channels that are like blood vessels down to about 100-micron diameter.   “There were several key technical developments to the FRESH printing technology that enabled this work,” described Daniel Shiwarski, assistant professor of bioengineering at the University of Pittsburgh and prior postdoctoral fellow in the Feinberg lab. “By implementing a single-step bioprinting fabrication process, we manufactured collagen-based perfusable CHIPS in a wide range of designs that exceed the resolution and printed fidelity of any other known bioprinting approach to date. Further, when combined with multi-material 3D bioprinting of ECM proteins, growth factors, and cell-laden bioinks and integration into a custom bioreactor platform, we were able to create a centimeter-scale pancreatic-like tissue construct capable of producing glucose-stimulated insulin release exceeding current organoid based approaches.” https://scitechdaily.com/scientists-bioprint-living-tissues-that-could-revolutionize-diabetes-treatment/ XX Another study showing the blood sugar benefit of walking after a meal. Skeletal muscle plays a central role in glucose uptake. Exercise stimulates glucose transport into muscle cells through insulin-independent pathways, notably through the action of glucose transporter type 4 (GLUT-4), which is responsible for transporting glucose from blood to skeletal muscles.4 This means that even without a robust insulin response, physical activity can facilitate glucose clearance from the bloodstream. These effects also occur without requiring high-intensity exercise, making postprandial walking accessible to a broad range of individuals, including those with limited exercise tolerance. multiple studies show that starting activity within 30 minutes after a meal is optimal. https://www.news-medical.net/health/Walking-After-Meals-Small-Habit-Big-Metabolic-Gains.aspx XX Dexcom brings back Dexcom U for a 4th years. This is a name, image and license program for college athletes with diabetes and includes a nationwide open call for passionate and inspiring college athletes to join its roster. Now through May 23, athletes, coaches, friends and family members can nominate candidates through an online submission. Those selected, along with the eight returning athletes from last year, will be invited to attend the Dexcom U Signing Day Camp this summer, hosted by Dexcom Warrior and Baltimore Ravens tight end Mark Andrews. https://www.hmenews.com/article/dexcom-u-returns-for-fourth-season

Adam, der erste Mensch mit einem nicht ganz zuverlässigen Insulinmanagement, ringt im Garten Eden mit einem uralten Problem: Essen oder nicht essen?

Zwischen Gewitter‑Pathos und Slapstick‑Chaos erfahrt ihr, wie der Weltuntergang an leeren Teststreifen scheitert, warum eine Porridge‑Schüssel gefährlicher sein kann als sieben Posaunen – und wieso diese Truppe die schlechteste Diabetes‑Selbsthilfegruppe aller Zeiten ist.  -- [Werbung]  Die Folge wird präsentiert von FreeStyle Libre Messystem – dem derzeit kleinsten und flachsten Sensor der Welt. Nach einer Aktivierungszeit von 60 Minuten misst der Sensor jede einzelne Minute. Weitere Infos und Hinweise zum FreeStyle Libre Messsystem: https://www.freestylelibre.de/produkte/freestyle-libre-3-entdecken.html [Werbung] Show Notes Weitere Infos zu FreeStyle Libre 3https://www.freestylelibre.de/produkte/freestyle-libre-3-entdecken.html www.freestylelibre.de Erwähnte Seiten, Blogs etc. 409 – Gott mit Diabetes Typ 1 – Neue Schöpfungslehre 405 – Vaterunser für Diabetiker 403 – Die Schöne und das „Dia“Biest 394 – Das Abenteuer von Insulin und dem bösen Zauberer Diabetikus

In dieser Episode spreche ich mit Personal Trainer Pat über ketogene Ernährung und exogene Ketone. Ihr erfahrt, wie sich Kohlenhydrate reduzieren lassen, warum das gerade bei Diabetes hilfreich sein kann und wie man trotz Verzicht auf Brot & Co. leistungsfähig bleibt. Pat teilt seine eigenen Erfahrungen und erklärt, warum es so wichtig ist, bei all diesen Themen den Blutzucker im Auge zu behalten und Rücksprache mit dem Diabetologen zu halten. -- [Werbung]  Die Folge wird präsentiert von FreeStyle Libre Messystem – dem derzeit kleinsten und flachsten Sensor der Welt. Nach einer Aktivierungszeit von 60 Minuten misst der Sensor jede einzelne Minute. Weitere Infos und Hinweise zum FreeStyle Libre Messsystem: https://www.freestylelibre.de/produkte/freestyle-libre-3-entdecken.html [Werbung] Show Notes Weitere Infos zu FreeStyle Libre 3https://www.freestylelibre.de/produkte/freestyle-libre-3-entdecken.html www.freestylelibre.de Erwähnte Seiten, Blogs etc. 307 – Coach Pat – Ich esse nicht und werde trotzdem dick 149 – Coach Pat – FPE – Warum Junkfood zum Testen von FPEs 354 – Eiweiß braucht keiner und was juckt es den Darm? 391 – KETO Live Project – Josephine Barbarino 392 – KETO Live Project – Josephine Barbarino Teil 2v2

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: Learning more about the FDA letter sent to Dexcom, news from ATTD including a bihormonal pump from a Dutch company, time in tight range update, more studies about using insulin and GLP-1 medications, eating chili to prevent gestational diabetes (really!) and more..  Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom   Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links: Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX Our top story this week: Dexcom Dive Brief: A warning letter posted Tuesday by the Food and Drug Administration revealed quality control issues with Dexcom's continuous glucose monitors. The FDA raised concerns with a design change to a component used in the resistance layer of Dexcom's sensors. The sensors with the new component were less accurate than those with the original component, according to the warning letter. Dexcom has ceased distribution of G7 sensors with the component, but the company's response did not address affected G6 sensors. J.P. Morgan analyst Robbie Marcus wrote in a research note Tuesday that the letter concerns a chemical compound that the sensor wire is dipped in. Dexcom began producing the compound internally to add redundancy to its supply chain.   Dive Insight: Dexcom Chief Operating Officer Jake Leach said in an interview with MedTech Dive last week that the company does not expect the warning letter to affect future product approvals, including a 15-day version of its G7 CGM, and there's no need yet to recall products. Dexcom has submitted the device to the FDA and anticipates a launch in the second half of the year.   Marcus, after speaking to company leadership and a quality control expert, wrote that many of the issues outlined in the letter could be addressed quickly. He added that the warning letter could explain minor delays in approval to the 15-day sensor, but Dexcom is still within the 90-day window for a 510(k) submission.   “While there's always a risk this could impede future product approvals,” Marcus wrote, “we do not expect this to materially delay the 15 day G7 sensor approval.”   The warning letter followed an FDA inspection last year of Dexcom's facilities in San Diego and Mesa, Arizona. Marcus wrote that after the FDA requested additional information and a separate 510(k), Dexcom stopped in-sourcing the compound and reverted back to the external supplier.   Dexcom's devices were misbranded because the company did not submit a premarket notification to the FDA before making major changes to the sensors, according to the warning letter. The sensors with the changed coating “cause higher risks for users who rely on the sensors to dose insulin or make other diabetes treatment decisions,” the letter said.     The FDA raised other concerns in the warning letter, including procedures to monitor the glucose and acetaminophen concentrations used in testing of the G6 and G7 CGMs. The FDA also cited problems with Dexcom's handling last year of a deficiency in its G6 sensors with dissolved oxygen content values, a key input for measuring blood glucose levels. https://www.medtechdive.com/news/dexcom-warning-letter-cgm-coating-change/743597/ XX Lots of studies and info out of the recent ATTD conference. One highlight that has been sort of under the radar: a Dutch company has been using a Bihormonal fully closed-loop system for the treatment of type 1 diabetes in the real world. This is a company called Inreda (in-RAY-duh). The Inreda AP® is an automatic system (closed loop) and independently regulates the blood glucose level by administering insulin and glucagon. The AP5 is certified in Europe and is being used in multiple studies and projects. The AP®6 is currently under development. https://www.inredadiabetic.nl/en/discover-the-ap/ https://pubmed.ncbi.nlm.nih.gov/38443309/ XX Let's talk about time in tight range. If you follow me and diabetes connections on social, you likely saw a video I made about this – it blew up last week. If not.. time in range has been a metric for a short while now.. in 2019 there was a consensus report advising a goal of 70% of time in the 70-180 mg/dL range for most people with type 1 diabetes (T1D) and type 2 diabetes (T2D), with modifications for certain subgroups. Recently we've been hearing more about 70-140 mg/dL — for longer periods as “time in tight range (TiTR).” At ATTD there was more talk about calling that range TING, or “time in normal glycemia.     There's a great writeup that I'll link up from the great Miriam Tucker on Medscape about a debate that happened at ATTD. On March 22, 2025, two endocrinologists debated this question at the Advanced Technologies & Treatments for Diabetes (ATTD) 2025. Anders L. Carlson, MD, medical director of the International Diabetes Center (IDC), Minneapolis, took the positive side, while Jeremy Pettus, MD, assistant professor of medicine at the University of California San Diego, who lives with T1D himself, argued that it's too soon.   https://www.medscape.com/viewarticle/should-time-tight-range-be-primary-diabetes-goal-2025a100073q?form=fpf   XX Sequel Med Tech announces its twist pump will be firs paired with Abbott's FreeStyle Libre 3 Plus. The twist has FDA approval for ages 6 and up and is set to begin its commercial launch by the end of June. The pump—designed by inventor Dean Kamen's Deka Research & Development—also incorporates the FDA-cleared Tidepool Loop software program, to record CGM blood sugar readings, make predictions based on trends and adjust its background insulin levels accordingly. https://www.fiercebiotech.com/medtech/sequel-med-tech-connects-twiist-insulin-pump-abbotts-cgm-ahead-market-debut XX Dexcom's longer-lasting CGM sensor looks promising, based on study results presented at the conference. The trial showed that the new 15-day G7 system is slightly more accurate than the current G7. The accuracy of CGM can be measured using MARD (mean absolute relative difference), which shows the average amount a CGM sensor varies from your actual glucose levels (a lower number is better).  The 15-day G7 has a MARD value of 8.0%, about the same as the Abbott Freestyle Libre 3. The Dexcom G7 15 Day is awaiting FDA approval and is not yet available in the U.S.   XX Little bit of news from Modular Medical.. they plan to submit their patch pump to the FDA late summer or fall of this year. The MODD1 product, a 90-day patch pump, features new microfluidics technology to allow for the low-cost pumping of insulin. Its new intuitive design makes the product simple to use and easier to prescribe. It has a reservoir size of 300 units/3mL. Users can monitor the pump activity with their cell phone and do not require an external controller. The pump uses a provided, single-use, disposable battery. Modular Medical picked up FDA clearance for MODD1 in September. The company also raised $8 million to end 2024. Its founder, Paul DiPerna, previously founded leading insulin pump maker Tandem Diabetes Care. DiPerna invented and designed Tandem's t:slim pump. By developing its patented insulin delivery technologies, the company hopes to improve access to glycemic control. Its founder, Paul DiPerna, previously founded leading insulin pump maker Tandem Diabetes Care. DiPerna invented and designed Tandem's t:slim pump. https://www.drugdeliverybusiness.com/modular-medical-announces-12m-private-placement/ XX More from attd – type 2 news? https://www.drugdeliverybusiness.com/biggest-diabetes-tech-news-attd-2025/ XX Another study that says people with type 1 who use a GLP-1 medication get better outcomes. In this study, those who use GLP-1 with insulin are 55% less likely to have a hyperglycemia-related ED visit, 26% less likely to have an amputation-related visit, and 29% less likely to have a diabetic ketoacidosis (DKA)-related ED visit in the following year compared to those on insulin alone. Although they are not approved for T1D, some patients may receive them off-label or for weight control. Pretty big study for an off label drug: compared 7,010 adult patients with T1D who were prescribed GLP-1s and insulin to 304,422 adult patients with T1D who were on insulin alone.  It is important to note that the rates of new diabetic complications in one year for both groups were around 1%, indicating that these are uncommon outcomes regardless of medication use. https://www.epicresearch.org/articles/some-diabetic-complications-less-likely-among-type-1-diabetics-on-glp-1s   XX Early research here but exposure to antibiotics during a key developmental window in infancy may stunt the growth of insulin-producing cells in the pancreas and boost risk of diabetes later in life The study, is published this month in the journal Science, it's a study in mice. These researchers are working off the idea that when while identical twins share DNA that predisposes them to Type 1 diabetes, only one twin usually gets the disease. She explained that human babies are born with a small amount of pancreatic “beta cells,” the only cells in the body that produce insulin.   But some time in a baby's first year, a once-in-a-lifetime surge in beta cell growth occurs.   “If, for whatever reason, we don't undergo this event of expansion and proliferation, that can be a cause of diabetes,” Hill said.   They found that when they gave broad-spectrum antibiotics to mice during a specific window (the human equivalent of about 7 to 12 months of life), the mice developed fewer insulin producing cells, higher blood sugar levels, lower insulin levels and generally worse metabolic function in adulthood.   in other experiments, the scientists gave specific microbes to mice, and found that several they increased their production of beta cells and boosted insulin levels in the blood. When male mice that were genetically predisposed to Type 1 diabetes were colonized with the fungus in infancy, they developed diabetes less than 15% of the time. Males that didn't receive the fungus got diabetes 90% of the time. Even more promising, when researchers gave the fungus to adult mice whose insulin-producing cells had been killed off, those cells regenerated. Hill stresses that she is not “anti-antibiotics.” But she does imagine a day when doctors could give microbe-based drugs or supplements alongside antibiotics to replace the metabolism-supporting bugs they inadvertently kill.   .   “Historically we have interpreted germs as something we want to avoid, but we probably have way more beneficial microbes than pathogens,” she said. “By harnessing their power, we can do a lot to benefit human health.”     https://www.eurekalert.org/news-releases/1078112 XX Future watch for something called BeaGL - created by researchers at the University of California Davis and UC Davis Health who were inspired by their own personal experiences with managing T1D.   BeaGL is designed to work with CGMs and has security-focused machine learning algorithms to make predictive alerts about anticipated glucose changes, which are sent to a device. In this case, a smartwatch. The end goal is for BeaGL to be completely automated to reduce the cognitive load on the patient, particularly for teens. It's still in research phase but six student with T1D have been using it for almost a year.     https://health.ucdavis.edu/news/headlines/with-ai-a-new-metabolic-watchdog-takes-diabetes-care-from-burden-to-balance/2025/02 XX Investigators are searching for a way forward after two long-term diabetes programs were terminated following the cancellation of their National Institutes of Health (NIH) funding, the result of federal allegations that study coordinator Columbia University had inappropriately handled antisemitism on campus. The programs include the three-decades-old Diabetes Prevention Program (DPP) and its offshoot, the Diabetes Prevention Program Outcomes Study (DPPOS). “We are reeling,” said David Nathan, MD, a previous chair of both the DPP and the DPPOS and an original leader of the landmark Diabetes Control and Complications Trial. Nathan is also founder of the Massachusetts General Hospital Diabetes Center in Boston, one of the 30 DPPOS sites in 21 states. On March 7, the Trump administration cancelled $400 million in awards to Columbia University from various federal agencies. While Columbia University agreed on March 21 to changes in policies and procedures to respond to the Trump administration's charges, in the hopes that the funding would be restored, DPPOS Principal Investigator Jose Luchsinger, MD, told Medscape Medical News that as of press time, the study was still cancelled. https://www.medscape.com/viewarticle/diabetes-prevention-program-cancellation-colossal-waste-2025a100076h XX XX Type 2 diabetes may quietly alter the brain in ways that mimic early Alzheimer's. This was only an animal study – but researchers say the high comorbidity of type 2 diabetes (T2D) with psychiatric or neurodegenerative disorders points to a need for understanding what links these diseases.   https://scitechdaily.com/how-diabetes-quietly-rewires-the-brains-reward-and-memory-system/ XX Eating chili once a month when you're pregnant seems to lower the risk of developing gestational diabetes. This is a real study! While chili showed a link to lower gestational diabetes risk, dried beans and bean soup had no significant effect, even among women who ate them more frequently. Some studies suggest that diets high in beans and legumes, including the Mediterranean diet, reduce GDM risk. While studies link beans to lower diabetes risk, their specific impact on GDM remains unclear. This study analyzed data from 1,397 U.S. pregnant women who participated in the Infant Feeding Practices Study II, conducted between 2005 and 2007. Chili consumption varied significantly by race, education, household size, income, supplemental nutrition status, and region. Non-Hispanic Black mothers consumed the most (0.33 cups/week), while those with higher income and education levels consumed less. Regional differences also influenced chili intake. One possible mechanism for chili's effect is capsaicin, a bioactive compound found in chili peppers, which has been linked to metabolic benefits in other studies. However, further research is needed to confirm this potential role in GDM prevention. Dried bean and bean soup consumption had no clear association with GDM. The study highlights limitations due to self-reported dietary data and the need for more detailed dietary measures. https://www.news-medical.net/news/20250317/Could-a-little-spice-in-your-diet-prevent-gestational-diabetes.aspx XX

Eine geführte Alpenüberquerung speziell für Menschen mit Diabetes. Ivo schildert, wie er die Tour bereits einmal allein bewältigt hat und nun mithilfe von Sponsoren acht weiteren Diabetikerinnen und Diabetikern ermöglichen möchte, diese rund neuntägige Wanderung auf einer sicheren und zugleich herausfordernden Route zu meistern. -- [Werbung]  Die Folge wird präsentiert von FreeStyle Libre Messystem – dem derzeit kleinsten und flachsten Sensor der Welt. Nach einer Aktivierungszeit von 60 Minuten misst der Sensor jede einzelne Minute. Weitere Infos und Hinweise zum FreeStyle Libre Messsystem: https://www.freestylelibre.de/produkte/freestyle-libre-3-entdecken.html [Werbung] Show Notes Weitere Infos zu FreeStyle Libre 3https://www.freestylelibre.de/produkte/freestyle-libre-3-entdecken.html www.freestylelibre.de Erwähnte Seiten, Blogs etc. Informationen zur Alpenüberquerung 2025 und Bewerbung findest Du hier: https://www.dialetics.com/events/dialetics-xalps-alpenueberquerung-mit-diabetes 342 – Ivo Rettig Alpenüberquerung – Auf und Ab mit Diabetes 274 – Ivo Rettig – Diabetes sollte kein Hindernis sein 388 – Vegane Ernährung als Diabetiker? – Talkrunde Kontaktdaten Ivo von DIALETiCS Instagram: https://www.instagram.com/mydialetics Webseite: https://www.dialetics.com/  

  In diesem Podcastinterview spreche ich mit Eva und Tina, den Macherinnen des „Type Wonderfull“-Podcasts. -- [Werbung]  Die Folge wird präsentiert von FreeStyle Libre Messystem – dem derzeit kleinsten und flachsten Sensor der Welt. Nach einer Aktivierungszeit von 60 Minuten misst der Sensor jede einzelne Minute. Weitere Infos und Hinweise zum FreeStyle Libre Messsystem: https://www.freestylelibre.de/produkte/freestyle-libre-3-entdecken.html [Werbung] Show Notes Weitere Infos zu FreeStyle Libre 3https://www.freestylelibre.de/produkte/freestyle-libre-3-entdecken.html www.freestylelibre.de Erwähnte Seiten, Blogs, Events T1Day – https://t1day.de – Ein jährliches Diabetes-Event in Berlin, bei dem sich Typ-1-Diabetikerinnen und Diabetiker treffen, austauschen und Vorträge besuchen. 152 – Die Zuckerschnuten – Alkohol & Insulin – Live und in Farbe 147 – Andrea Witt – Zuckerschnuten mit Diabetes Helferherzen – 276 – KLAFA Klassenfahrtbetreuung für Kinder mit Diabetes Typ 1 Kontaktdaten E-Mail-Adresse: typeonederful.podcast@gmail.com Spotify: TYPE-ONE-DER-FUL – Der Diabetes-Podcast YouTube: @typeonederful-podcast Instagram: @typeonederful_podcast

In dieser Podcast-Folge spreche ich mit Timm Roos, der maßgeblich am DT-Report beteiligt ist – einer jährlichen Erhebung zu Digitalisierung und Technologie im Diabetes-Management. Wir tauchen ein in spannende Themen: Wie verbreitet sind CGM und AID-Systeme? Warum erleben viele Technologiestress? Welche Rolle spielen smarte Insuline? Außerdem geht's um die Unterschiede zwischen Deutschland, Österreich und der Schweiz, den Schulungsbedarf und die Forderung nach besserem Support – Stichwort 24h-Hotline. Nachhaltigkeit in der Diabetes-Technologie? Noch kein großes Kriterium, aber der Wunsch ist da! -- [Werbung]  Die Folge wird präsentiert von FreeStyle Libre Messystem – dem derzeit kleinsten und flachsten Sensor der Welt. Nach einer Aktivierungszeit von 60 Minuten misst der Sensor jede einzelne Minute. Weitere Infos und Hinweise zum FreeStyle Libre Messsystem: https://www.freestylelibre.de/produkte/freestyle-libre-3-entdecken.html [Werbung] Show Notes Weitere Infos zu FreeStyle Libre 3https://www.freestylelibre.de/produkte/freestyle-libre-3-entdecken.html www.freestylelibre.de Kontaktdaten Webseite: https://dt-report.de/ E-Mail: dt-report@fidam.de

In dieser Podcast-Episode entführe ich euch in ein verzaubertes Schloss, in dem Bella und das Biest nicht nur einen alten Fluch, sondern auch Diabetes Typ 1 überwinden müssen.    [Werbung]  Die Folge wird präsentiert von FreeStyle Libre Messystem – dem derzeit kleinsten und flachsten Sensor der Welt. Nach einer Aktivierungszeit von 60 Minuten misst der Sensor jede einzelne Minute. Weitere Infos und Hinweise zum FreeStyle Libre Messsystem: https://www.freestylelibre.de/produkte/freestyle-libre-3-entdecken.html [Werbung] Show Notes Weitere Infos zu FreeStyle Libre 3https://www.freestylelibre.de/produkte/freestyle-libre-3-entdecken.html www.freestylelibre.de

[Werbung]  Die Folge wird präsentiert von FreeStyle Libre Messystem – dem derzeit kleinsten und flachsten Sensor der Welt. Nach einer Aktivierungszeit von 60 Minuten misst der Sensor jede einzelne Minute. Weitere Infos und Hinweise zum FreeStyle Libre Messsystem: https://www.freestylelibre.de/produkte/freestyle-libre-3-entdecken.html [Werbung] Show Notes Weitere Infos zu FreeStyle Libre 3https://www.freestylelibre.de/produkte/freestyle-libre-3-entdecken.html www.freestylelibre.de Erwähnte Seiten, Blogs etc. 341 – Dirty Talk mit Pumpe und Pen – Michelle Schmidt 307 – Coach Pat – Ich esse nicht und werde trotzdem dick 391 – KETO Live Project – Josephine Barbarino 186 – Die 4 Kompetenzen eines Diabetikers

In this episode of The Good Health Podcast, we dive into the groundbreaking advancements in medical wearables set to revolutionize health and wellness in 2025. From tracking glucose levels to managing stress, these devices have evolved far beyond step counters, offering precision and actionable insights. We explore how these tools empower individuals to take charge of their health, enabling proactive changes and better outcomes, whether you're managing a chronic condition or optimizing overall wellness.Discover the top wearables dominating the market, including continuous glucose monitors like Dexcom G8 and Freestyle Libre 4, versatile smartwatches such as the Apple Watch Series 10 and Garmin Venu 3 Plus, and niche devices like the Apollo Neuro and Oura Ring. We break down their features, benefits, and use cases, helping you find the perfect match for your health goals. Whether it's enhancing sleep quality, reducing stress, or boosting performance, these wearables deliver the data you need to thrive.We also addresses the ethical and practical considerations of using wearables, including data privacy and avoiding overreliance on metrics. Learn how to integrate these tools into a balanced, holistic health strategy for lasting results. Don't miss this ultimate guide to staying ahead of the curve in health tech.DISCLAIMER: The content in this podcast and related website is not intended to be a substitute for medical advice. It is not intended to be used to diagnose or treat, instead it is designed to help educate and inspire. Always seek the advice of a professional medical practitioner or qualified health practitioner. Never ignore or disregard advice given to you based on information in this podcast or related website and do not delay in seeking medical advice.RESOURCES: Grab all the links and resources mentioned in this episode at https://www.nicolegoodehealth.com/the-goode-health-podcast/episode-69

[Werbung]  Die Folge wird präsentiert von FreeStyle Libre Messystem – dem derzeit kleinsten und flachsten Sensor der Welt. Nach einer Aktivierungszeit von 60 Minuten misst der Sensor jede einzelne Minute. Weitere Infos und Hinweise zum FreeStyle Libre Messsystem: https://www.freestylelibre.de/produkte/freestyle-libre-3-entdecken.html [Werbung] Show Notes Weitere Infos zu FreeStyle Libre 3https://www.freestylelibre.de/produkte/freestyle-libre-3-entdecken.html www.freestylelibre.de Erwähnte Seiten, Blogs etc. 398 – Diability GmbH – Michelle Schmidt 363 – Ruhig Blut(zucker) – wenn Du morgen sterben würdest

I catch up with Samsung's Blake Gaiser, Head of Smartphone Product Management, at the Galaxy Unpacked event in San Jose, to hear all about the incredible AI features backed into the new family of Samsung Galaxy S25 devicesFrom laptops and desktops to automotive news, we'll learn about Intel's highlights from CES with Asma Aziz, Marketing Director for the Americas, at IntelCalled ‘Lingo,' we'll get the 4-1-1 on a new biowearable from Abbott – and find out how it differs from the Freestyle Libre device for those with diabetes -- I interview Pamela Nisevich Bede, Global Nutritionist at Abbott's Lingo Business.Thank you to Intel, Visa, and SanDisk 

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: Dexcom updates investors on its 15-day sensor, TrialNet marks a big anniversary, Beta Bionics goes public, NFL fans support Mark Andrews and much more! Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom  Edgepark Medical Supplies Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens  Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links: Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX Couple of quick updates from the JP Morgan Healthcare Conference. Dexcom's CEO Kevin Sayer expects to launch a 15-day sensor in the second half of the year. That's in front of the FDA right now. Competitor Abbott currently has 15-day sensors with its Freestyle Libre 2 Plus and Freestyle Libre 3 Plus devices, which the FDA cleared in 2023. Sayer also talked about expanded insurance coverage for the G7, to include more people with type 2. They haven't pursued that with Stelo, the OTC version of their sensors. The company has begun work on a next-generation CGM. Sayer said the sensor will be smaller, less expensive and include better electronics. Dexcom is also studying new sensor probes, one of which can support multiple analytes, such as measuring lactate or ketones in addition to insulin.   https://www.medtechdive.com/news/dexcom-ceo-stelo-otc-strategy-jp-morgan/737424/ XX TrialNet reaches a big milestone – more than a quarter million people have learned their risk of developing T1D through screening. TrialNet screening is available to family members of those diagnosed with T1D. Having a family history of the disease places individuals at a 15 times greater risk than those with no family members with T1D. Over the course of VUMC's 18 years participating in the program, the community of T1D patients has become increasingly more engaged with research efforts. More than ever, there is an eagerness to give back to others by participating in clinical trials that could help revolutionize care for those diagnosed with or at risk of developing T1D. In such trials, TrialNet typically takes drugs already shown to be effective in treating other autoimmune diseases and seeks to determine their efficacy in treating, delaying or preventing T1D.   Spencer Mannahan, a 10-year-old patient at Monroe Carell Jr. Children's Hospital at Vanderbilt, is participating in a TrialNet study that is looking to determine whether a treatment regimen using both rituximab and abatacept can preserve insulin production in patients newly diagnosed with T1D. Russell, one of the PIs for the study (Protocol TN-25), also treated Spencer's father, Zach, when he was diagnosed with T1D as a child. She enrolled in a different TrialNet study (Protocol TN-31) examining the effect of abrocitinib and ritlecitinib on insulin production in newly diagnosed individuals. While the possibility exists that her insulin production could be preserved, O'Neal joined the study because it presented an opportunity to make a positive impact on future patients.     These clinical trials support TrialNet's goal of a future without T1D. Research is underway on new methods of blocking the advance of T1D in patients with diabetes-related antibodies. One study will investigate whether T cells that have been activated against insulin can be specifically targeted, rather than issuing a treatment that targets all the body's T cells (thus rendering the patient immunocompromised).   TrialNet, the largest clinical trial network assembled to change the course of Type 1 diabetes, is funded by the National Institutes of Health through grant number NCT00097292.   For more information about screening for Type 1 diabetes risk if it runs in your family, contact info@trialnet.org, visit www.trialnet.org, or contact the Vanderbilt Type 1 Diabetes TrialNet Program at 615-936-8638. https://news.vumc.org/2025/01/22/milestone-in-vumc-affiliated-diabetes-screening-and-research-program-underscores-impact-of-clinical-trials/   XX Another study links air pollution to type 2 diabetes. This is from Wayne State University, and established a robust association between exposure to benzene, a prevalent airborne volatile organic compound, and insulin resistance in humans across all ages. “In this study, we exposed mice to benzene to see how it affects their blood glucose levels and energy expenditure,” she explained. “Our research revealed that within seven days of exposure, they developed high blood glucose insulin levels.” https://today.wayne.edu/medicine/news/2025/01/23/study-links-air-pollution-exposure-to-type-2-diabetes-susceptibility-65321 XX Adults with overweight or obesity and type 2 diabetes who are given the sodium glucose cotransporter 2 (SGLT-2) inhibitor drug dapagliflozin alongside moderate calorie restriction achieve much higher rates of remission compared with calorie restriction alone. The researchers say this study provides a practical strategy to achieve remission for patients with early type 2 diabetes. As well as helping to lower blood sugar levels, SGLT-2 inhibitors can also lead to weight loss, but their effect alongside calorie restriction on diabetes remission has not yet been investigated in a randomised controlled trial.   To address this, researchers carried out a trial involving 328 patients with type 2 diabetes of less than six years' duration at 16 centres in mainland China from 12 June 2020 to 31 January 2023.   Participants were aged 20-70 years with a body mass index (BMI) greater than 25 and were not taking any anti-diabetic medication other than metformin. https://www.news-medical.net/news/20250123/Dapagliflozin-and-calorie-restriction-show-higher-remission-rates-in-type-2-diabetes.aspx XX Beta Bionics has set the terms for its plan to go public, with a goal of raising at least $114 million to support its artificial pancreas system for people with Type 1 diabetes. That's as we're recroding, it's likely they will have begun trading on the NASDAQ by now.. the ticker is BBNX. Beta Bionics' iLet system was first cleared by the FDA for people ages six and up with Type 1 diabetes in May 2023. The Fierce Medtech Fierce 15 winner has since expanded its blood sugar sensor compatibility to include Abbott's FreeStyle Libre and Dexcom's G6 and G7 platforms. The company also said it plans to pursue new clinical studies and an FDA clearance that would enable the iLet's use among people with Type 2 diabetes. The ultmite goal is to have a dual-chambered pump with both insulin and glucagon.. but I didn't find anything about that in the articles about this IPO.. I followed up with Beta Bionics and they told me that the dual chambered pump is still very much the goal. Not sure why most of the publications left that out.. but good to hear. https://www.fiercebiotech.com/medtech/artificial-pancreas-maker-beta-bionics-aims-raise-120m-nasdaq-ipo XX Large new study estimates the size of the current US population with type 1 diabetes and project growth over the next ten years. They say about 2 million live with type 1.. about 1.79 million adults and 290-thousand children. Growth in the ten years is predicted to be about 10% https://jheor.org/article/124604 XX The American Diabetes Association® (ADA) teams up with Xeris Pharmaceuticals® makers of Gvoke – ready to use emergency glucagon. It is estimated that up to 46% of people with type 1 diabetes and 21% of those with type 2 diabetes using insulin experience at least one severe hypoglycemia event each year.2 The ADA, with support from Xeris, seeks to rectify the low rates of appropriate glucagon prescriptions by developing education materials and training resources for health care professionals and people living with diabetes, as well as through a national awareness campaign to educate people on who is at risk for severe hypoglycemia and should have glucagon, preferably ready-to-use, as a safety net. https://www.prnewswire.com/news-releases/the-american-diabetes-association-and-xeris-pharmaceuticals-announce-national-collaboration-to-provide-life-saving-hypoglycemia-education-and-awareness-302355703.html XX XX Wearing a CGM makes pharmacy students better at counseling patients. New study randomly assigned students to wear a CGM during lab sessions.. those who did had a higher average counseling score during the encounter with a patient and a higher overall confidence score. There was also a statistically significant positive correlation between average confidence and average empathy, and empathy and counseling performance. https://www.drugtopics.com/view/hands-on-cgm-training-helps-student-pharmacists-prepare-for-career XX Mark Andrews Bills Mafia Baltimore Ravens tight end Mark Andrews received a host of negative attention after flubbing a potential game-tying two-point conversion in Sunday night's loss to the Buffalo Bills.   In the face of the online rage, Bills Mafia is again showing some support.   Bills fan Nicholas Howard kicked off a GoFundMe to back Breakthrough T1D, a global Type 1 diabetes research organization that Andrews has supported.   "As many of you know, Ravens TE wasn't able to catch the game-tying 2-point conversion and upset Ravens fans," Howard wrote. "On top of that, the TE has been receiving death threats and nasty comments after his performance last night. We want Bills Mafia to donate to Marks charity for [Type 1] diabetes."   As of Wednesday morning, the fund raised more than $50,000 for the charity.   Related Links Lamar Jackson, Ravens bemoan missed opportunities in loss to Bills, defend Mark Andrews Ravens WR Zay Flowers: Missing 2024 playoff run due to injury 'took a little toll on me' Biggest winners and losers from Sunday's Divisional Round NFL playoff games The Ravens thanked Bills fans for supporting Andrews.     "Shout out to Bills Mafia for showing support to our guy Mark Andrews and donating to the [BreakthroughT1D] organization, which works towards curing and improving the lives of those dealing with Type 1 diabetes," the club posted.   Andrews was diagnosed with Type 1 diabetes as a child, an autoimmune disease for which there is currently no cure. He's one of several NFL players diagnosed with Type 1 -- Kansas City Chiefs tight end Noah Gray is another.   "Breakthrough T1D [formerly JDRF] greatly appreciates the generosity of the Buffalo Bills community and the many fans who were compelled to donate after Sunday's game," the organization said in a statement to ESPN's Alaina Getzenberg. "These donations will support research and advocacy on behalf of the 1.6 million Americans who, like Mark Andrews, live with type 1 diabetes."   It's not the first time that Bills fans have donated to the cause of a non-Buffalo player. Back in January 2018, Buffalo fans famously donated to the charity of former Cincinnati Bengals quarterback Andy Dalton after his win over Baltimore helped Buffalo make its first playoff appearance in nearly two decades. Over and over again, Bills Mafia has shown it will support a good cause when some spew hate. https://www.nfl.com/news/bills-fans-supporting-ravens-te-mark-andrews-after-drop-by-donating-to-type-1-diabetes-research

[Werbung]  Die Folge wird präsentiert von FreeStyle Libre Messystem – dem derzeit kleinsten und flachsten Sensor der Welt. Nach einer Aktivierungszeit von 60 Minuten misst der Sensor jede einzelne Minute. Weitere Infos und Hinweise zum FreeStyle Libre Messsystem: https://www.freestylelibre.de/produkte/freestyle-libre-3-entdecken.html [Werbung] Show Notes Weitere Infos zu FreeStyle Libre 3https://www.freestylelibre.de/produkte/freestyle-libre-3-entdecken.html www.freestylelibre.de Erwähnte Seiten, Blogs etc. 349 – Einmal Pen und zurück bitte – Michelle Schmidt 349 – Einmal Pen und zurück bitte – Michelle Schmidt 326 – Periode und Diabetes Typ 1 mit Michelle Schmidt 310 – Michelle Schmidt – mittendrin in der Weltreise 261 – Michelle Schmidt – Was bringt Dein Blutzucker in den Keller? 216 – Michelle Schmidt – Kein Kontakt zu Menschen mit Diabetes Kontaktdaten mydiability oder diabilityde Bock auf nen Job?: Jobs@Diability.de (michellemotiviert)

It's a question I see asked a lot. There's a whole Facebook group dedicated to discussing the issues parents have when their children are preparing to leave home for university, and the questions come in cycles. Right now, it's UCAS forms and university choices, as the deadline for applications looms. In a couple of months it will be questions about A-Level revision and exam dates, and then will come the angst - in rafts - over teenagers whose parents don't think they're ready. (I have a sneaking suspicion it's the parents who aren't ready most of the time, not the kids.My guest in this episode speaks to this parental fear as a parent herself, and as a psychologist who supports families of children and teenagers with type 1 diabetes. Professor Deborah Christie talks about how any disability makes it more difficult to leave home, especially for the often chaotic lifestyle of university. With data* suggesting that over a third of young adults have a long-term physical or mental health condition, disability or illness, could this be something your listeners might be interested in? Deborah offers reassurance and tips for success, whatever your fears for your child as they gain independence and have to look after themselves. * Research commissioned to mark the integration of Abbott's FreeStyle Libre 2 Plus sensor withInsulet's Omnipod® 5 Automated Insulin Delivery System.More for parents of teenagers preparing for university Don't fear the empty nest (podcast) 10 Tips for coping with empty nest syndrome (read) Being diagnosed with diabetes as a teenager (podcast) How to keep your teen safe at university (read) 60 Gifts for university students (list)Who is Deborah Christie? Deborah Christie is a professor of paediatric and adolescent psychology at University College London NHS Foundation Trust and Dartford and Gravesham NHS Trust. She is an internationally respected academic and award-winning clinician; with an outstanding record of peer-reviewed publications, teaching and leadership with over 200 peer reviewed papers and chapters and a bestselling book, Psychosocial Aspects of Diabetes in Children, Adolescents and Families. She co-authored the expert reports on Psychosocial Issues of infection and the Impact of bereavement for the UK government Infected Blood Inquiry.Who is Helen?Helen wills is a counsellor, a parent coach, and a teen mental health podcaster and blogger at Actually Mummy, a resource for midlife parents of teens.For information on your data privacy please visit Zencastr's policy pagePlease note that Helen Wills is not a medical expert, and nothing in the podcast should be taken as medical advice. If you're worried about yourself or a teenager, please seek support from a medical professional.Episode produced by Michael J Cunningham.

[Werbung]  Die Folge wird präsentiert von FreeStyle Libre Messystem – dem derzeit kleinsten und flachsten Sensor der Welt. Nach einer Aktivierungszeit von 60 Minuten misst der Sensor jede einzelne Minute. Weitere Infos und Hinweise zum FreeStyle Libre Messsystem: https://www.freestylelibre.de/produkte/freestyle-libre-3-entdecken.html [Werbung] Show Notes Weitere Infos zu FreeStyle Libre 3https://www.freestylelibre.de/produkte/freestyle-libre-3-entdecken.html www.freestylelibre.de Erwähnte Seiten, Blogs etc. 395 – Diabetes trifft Bodybuilding: Mit Training und Ernährung Grenzen sprengen Was liest Du, hast Du gelesen bzw. gehört (Hörbuch) und was kannst Du empfehlen? Die Schriften von Accra von Paulo Coelho Der Alchemist von Paulo Coelho Kontaktdaten Auf allen Plattformen: Lala.laraa_

[Werbung]  Die Folge wird präsentiert von FreeStyle Libre Messystem – dem derzeit kleinsten und flachsten Sensor der Welt. Nach einer Aktivierungszeit von 60 Minuten misst der Sensor jede einzelne Minute. Weitere Infos und Hinweise zum FreeStyle Libre Messsystem: https://www.freestylelibre.de/produkte/freestyle-libre-3-entdecken.html [Werbung] Show Notes Weitere Infos zu FreeStyle Libre 3https://www.freestylelibre.de/produkte/freestyle-libre-3-entdecken.html www.freestylelibre.de Erwähnte Seiten, Blogs etc. Kontaktdaten Instagram: @coachguido Webseite: https://coach-guido.de/

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: A push to change the defined stages of T1D, InsuJet is approved in Canada, new study linked T2D and dementia, new drug looked at to prevent hypoglycemia, big honors for a T1D author and more! Our interview with Clare Edge here.  Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom  Edgepark Medical Supplies Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens  Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links:     Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX   The understanding of type 1 has changed a lot in the last 10-15 years, specifically with the definition of stages of the disease. Now some researchers suggest the current 2015 model is ready for another update. University of Florida Health diabetes researchers and collaborators last week issued a call to action in The Lancet Diabetes & Endocrinology, urging the development of a more precise method of calculating type 1 diabetes risk. Under the current staging system, this is Stage 1 of the disease, when a patient does not yet have elevated blood sugar but has two or more of these autoantibodies in the blood. Stage 2 is diagnosed when blood sugar begins to rise, indicating a dysfunctional pancreas in a patient who does not yet have clinical type 1 diabetes. That comes in Stage 3 with high blood sugar and, eventually, the classic symptoms of the disease, including frequent urination, weight loss and fatigue. Jacobsen, however, said the staging system requires more precision. This is especially important as the current staging model determines if a patient is eligible to receive a drug therapy called teplizumab, the only Food and Drug Administration-approved medication that can delay the onset of type 1 diabetes by an average of two years. The staging system, however, does not include a patient's age and these researchers say additional markers that would be important to consider include a greater array of abnormal metabolic measures beyond blood sugar and the presence of more autoantibodies.   https://www.gainesville.com/story/news/healthcare/2024/12/04/uf-health-scientists-propose-update-to-type-1-diabetes-staging-system/76734459007/ XX A product called InsuJet gets approval in Canada. Made by NuGen Medical Devices, InsuJet™ is a needle-free injection system. It's already approved for sale in 42 countries – not yet the US. Their website says InsuJet's jet-injected fluid penetrates the skin through a small orifice of a special nozzle, creating a thin, high pressure stream. This way, insulin doesn't remain around the place of injection, like it does with a needle. Instead, with InsuJet, the insulin is deposited into the subcutaneous tissue where it's easily absorbed and acts faster– saving you money, time, and discomfort.   https://finance.yahoo.com/news/nugen-announces-canada-wide-launch-221500674.html XX Individuals diagnosed with type 2 diabetes before the age of 50 may be at a higher risk of developing dementia later in life. A study led by researchers at NYU Rory Meyers College of Nursing, says the risk is notably greater among adults with obesity. Type 2 diabetes is a known risk factor for dementia. Although the underlying mechanisms are not fully understood, scientists think that some of the hallmarks of diabetes—such as high blood sugar, insulin resistance, and inflammation—may encourage the development of dementia in the brain.     The researchers note that this greater understanding of the connection between diabetes onset, obesity, and dementia may help inform targeted interventions to prevent dementia. https://scitechdaily.com/diagnosed-young-with-diabetes-your-dementia-risk-may-be-higher/ XX Embecta is out of the insulin patch pump business – just months after getting the ok from the FDA. Embecta received FDA clearance for its insulin patch pump in September. The device is indicated for people with Type 1 or Type 2 diabetes and includes a 300-unit insulin reservoir to support people with higher daily insulin needs. However, the version Embecta received clearance for was an open-loop patch pump, where users manually control insulin delivery, while the firm's goal was to develop a closed-loop version, which automatically delivers insulin when needed. The CEO also expects competition in closed-loop devices for people with Type 2 diabetes to intensify, with Insulet receiving FDA clearance for its Omnipod 5 patch pump for Type 2 diabetes in August. https://www.medtechdive.com/news/embecta-discontinue-patch-pump/734059/ XX Sanofi invests in a company developing a new drug to prevent hypoglycemia. We reported on Zucara Therapeutics back in 2022 and they've been moving ahead with ZT-01. ZT-01 is a medication being developed to help prevent dangerous low blood sugar (hypoglycemia) by fixing how the body normally fights it. In people without diabetes, a hormone called glucagon is released to raise blood sugar when it gets too low. But in people with insulin-dependent diabetes, like type 1 diabetes or some forms of type 2 diabetes, this process doesn't work well because another hormone, somatostatin (SST), blocks glucagon from being released. ZT-01 works by blocking the effects of somatostatin, allowing the body to release more glucagon when it's needed. This could help people with diabetes avoid severe low blood sugar episodes.   https://www.prnewswire.com/news-releases/zucara-therapeutics-announces-strategic-investment-from-sanofi-as-part-of-us20-million-series-b-financing-302301820.html XX Omnipod 5 is now compatible with the FreeStyle Libre 2 plus. The company says the recent development “ makes Omnipod 5 the most connected tubeless AID system in the U.S.” It's already compatible with Dexcom's G6 and G7 CGMs. https://www.businesswire.com/news/home/20241120268759/en/Insulet-Announces-Omnipod%C2%AE-5-System-is-Now-Compatible-with-Abbott%E2%80%99s-FreeStyle-Libre-2-Plus-Sensor-in-the-U.S. XX A new study involving 11 clinical centers across the United States aims to uncover how type 1 diabetes (T1D) impacts brain health and cognitive function in children. Led by the Keck School of Medicine of the University of Southern California, this is a five-year study to explore critical questions about how environmental, lifestyle, social and clinical factors affect brain development during childhood — a period crucial for cognitive growth. https://www.managedhealthcareexecutive.com/view/new-study-to-explore-impact-of-type-1-diabetes-on-children-s-brain-development XX Dexcom looking to partner with smart ring company Oura. Originally launched to track sleep patterns, the latest Oura technology collects more than 20 biometrics ranging from heart rate and activity metrics to sleep and body temperature monitoring. The companies say the new partnership is intended to provide users with seamless integration between the two ecosystems so shared users can track their glucose levels and understand the impact of behaviors and biology on their metabolic health. https://www.forbes.com/sites/saibala/2024/11/29/smart-ring-maker-oura-hits-5-billion-in-valuation--strikes-major-partnership-with-dexcom/ XX   WEDNESDAY, Dec. 4, 2024 (HealthDay News) -- Taking even high doses of supplementary vitamin D won't lower an older person's odds for type 2 diabetes, new research confirms. They published their findings Dec. 2 in the journal Diabetologia. The new research followed on data from other studies that had suggested that people with especially low levels of vitamin D might face a higher risk for diabetes. That was true for people who were already prediabetic, especially. To find out, researchers led by Jirki Vyrtanen, from the University of Eastern Finland, randomly assigned nearly 2,300 people aged 60 or older to receive either placebo pills or 40 or 80 micrograms of vitamin D3 supplements per day, for five years.  At the end of the five years, "105 participants developed type 2 diabetes: 38 in the placebo group, 31 in the group receiving 40 micrograms of vitamin D3 per day, and 36 in the group receiving 80 micrograms of vitamin D3 per day," according to a university news release. In other words, there were no significant differences in the rate at which people developed type 2 diabetes, regardless of how much supplemental vitamin D they took. Vytanen's team also saw no benefit from high-dose supplements on a person's blood sugar or insulin levels, or measures of overweight/obesity. The bottom line, according to the researchers: For any healthy, non-prediabetic person with healthy vitamin D levels, upping intake of the vitamin won't alter your odds for diabetes or its common risk factors. https://www.usnews.com/news/health-news/articles/2024-12-04/high-dose-vitamin-d-supplements-wont-prevent-diabetes-in-healthy-seniors XX Big congrats to author Clare Edge – recent guest on the podcast. Her book, Accidental Demons is featured on People Magazine's top ten book gift suggestions for this year! Whether you're looking for books about winter and the holidays, a primer on some of this year's buzziest musicians and characters or that "one more chapter" kind of bedtime favorite, there's sure to be a book out there to suit their taste. Bernadette Crowley, also known as Ber, comes from a long line of witches. When Ber is diagnosed with diabetes, however, she learns that every time she tests her blood sugar, demons accidentally slip into the human dimension — and it's up to Ber and her sister, Maeve, to stop them. This fantastical book is a great escape for young readers over holiday break. Buy Now Top ten books https://people.com/kids-gift-book-suggestions-wicked-taylor-swift-books-8752097

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: iPhone control for Omnipod 5 rolls out, Libre is approved for use in CT scans and MRIs, Dexcom files for 15 day wear, Luna nighttime pump goes to trial, iLet cell trials move forward and more! Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom  Edgepark Medical Supplies Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens  Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links: Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX Insulet Corporation announces the full market release of the Omnipod 5 App for iPhone® in the U.S. App allows users to fully control their Omnipod 5 Automated Insulin Delivery System (Omnipod 5) from their compatible iPhone1. For example, users can bolus for a meal, change a Pod, and adjust settings. Importantly, this also means that Omnipod 5 users who have a compatible iPhone no longer need to carry a separate Controller to help manage their insulin delivery requirements. Insulet says that the App for iPhone has been the number one feature requested by Omnipod 5 users. The Omnipod 5 App for iPhone is currently compatible with the Dexcom G6 Continuous Glucose Monitoring (CGM) System and is expected to be compatible with the Dexcom G7 CGM in the U.S. in 2025. The Omnipod 5 App for Android phones is also available to U.S. customers. https://www.businesswire.com/news/home/20241029838744/en/Omnipod%C2%AE-5-App-for-iPhone%C2%AE-Now-Fully-Available-in-the-United-States   XX Th FDA says it's okay to keep on your FreeStyle Libre 2 and 3 for procedures like X-rays, CT scans and MRIs. Abbott said it makes its systems the first and only patient-applied CGM sensors approved for these screenings. Imaging procedures often come as part of diabetes care, Abbott said, especially as diabetes can cause a number of medical complications. The company rigorously tested its Libre 2 and 3 sensors to ensure they remain effective after radiologic procedures. This FDA clearance comes with no changes made to the sensor.   https://www.drugdeliverybusiness.com/fda-approves-abbott-cgms-medical-imaging/ XX Tidepool announced a new data integration with Abbott for the company's FreeStyle Libre continuous glucose monitors (CGMs). The companies aim to deliver cloud-to-cloud integration for an automatic stream of data from patients using Abbott's CGMs in the U.S. Data streams to Tidepool+, a diabetes data visualization and population health platform. Tidepool+ provides intuitive tracking and visualization of diabetes data to make the data informative and actionable for clinicians, people with diabetes and caregivers. https://www.drugdeliverybusiness.com/tidepool-abbott-data-integration-freestyle-libre/ XX Beta Bionics announced today that it launched the integration of the iLet bionic pancreas with the Abbott (NYSE:ABT) FreeStyle Libre 3 Plus. The companies announced their plan to combine the FreeStyle Libre 3 Plus continuous glucose monitor (CGM) with iLet last month. According to Beta Bionics, this makes iLet the first available automated insulin delivery (AID) system to integrate with Libre 3 Plus in the U.S. iLet users can now update their app and software to gain a choice of integrated CGMs. They can choose between Libre 3 Plus and Dexcom CGMs.   Abbott, meanwhile, continues to push forward on the automated insulin delivery integration front. The company recently paired its FreeStyle Libre 2 Plus with Insulet's Omnipod 5 in Europe. It also announced compatibility with the Tandem Diabetes Care t:slim X2 system in January.   Notably, the company also struck a deal with Medtronic in August. They aim to develop CGMs specifically for the medtech giant's own insulin delivery systems. https://www.drugdeliverybusiness.com/beta-bionics-launches-ilet-abbott-libre/ XX Dexcom is asking the FDA to approve the G7 CGM for 15 days. Right now the G7 has a 10 day wear time.  Dexcom also launched the G7 CGM in Australia and rolled out Dexcom ONE+ in France. Some front-office news.. EVP and CCO Teri Lawver plans to retire at the end of the year. https://www.drugdeliverybusiness.com/dexcom-submits-15-day-cgm-fda-q3-2024/ XX Stelo by Dexcom is one of TIME's Best Inventions of 2024! As the first glucose biosensor available in the U.S. without a prescription, Stelo has unlocked our industry-leading technology for millions of people across the U.S. looking to improve their health through personalized insights. We're honored to be recognized among other unique innovations in the Home Health category that support people's health. https://time.com/7094684/dexcom-stelo/   XX   Luna Diabetes is moving forward with a pivotal trial evaluating its automated closed-loop insulin technology, the Luna System. This is designed to address nighttime glucose control for insulin pen users. It's meant for use only during sleep - Luna system was developed as a wearable insulin pump and alternative to insulin pen to automate the insulin delivery process. The device works with continuous glucose monitors (CGM) to calculate and deliver rapid-acting insulin doses during sleep. Luna Diabetes expects the study to be completed early next year, with plans to commercially launch the device “soon after”.   https://finance.yahoo.com/news/luna-diabetes-trials-automated-wearable-115211566.html?guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&guce_referrer_sig=AQAAAJIrWwjdye-ehrLNDt-LIGb5qTXaKDTIa8NWwiT7fKwFFgjDMN2nnINis6YfFePWP2ZA2DVYWXEIZQqRlQ4aKLFrYWgvw1jdI-t1n9kO6NIzdBCMXQNNCVl_S-75lDNip2SysHDJQmyqSc4wLjfDya3v9wwTWU-KgE_OqrPCTnlu XX Researchers are urging  caution when prescribing off-label glucose-lowering drugs to individuals with type 1 diabetes (T1D) while acknowledging that doctors keep prescribing them because they seem to work so well. Both glucagon-like peptide-1 receptor agonists (GLP-1RA) and sodium-glucose cotransporter 2 (SGLT2) inhibitors have shown significant benefits for cardiovascular and renal health in other populations, particularly in patients with type 2 diabetes.   SGLT2 inhibitors carry a significant risk of euglycemic diabetic ketoacidosis, a dangerous condition most common in T1D individuals where toxic levels of blood acidification can occur. Due to this risk, SGLT2 inhibitors were removed for T1D use in Europe, and the U.S. Food and Drug Administration (FDA) has not approved them for T1D.   For GLP-1RAs, there are concerns about substantial weight loss potentially leading to ketoacidosis or worsening hypoglycemia. While these medications can be beneficial in managing weight, the extent of that weight loss can create new problems in people with T1D as their insulin needs may quickly change as a result. Prescribing in People With Type 1 Diabetes," published in JAMA, the authors stress the critical need for more research to confidently allow the off-label usage of potentially dangerous secondary treatments. The data suggests clinicians are turning to these treatments to manage cardiovascular and renal complications in T1D patients, even though the drugs are not explicitly approved for this condition.   Conversely, those newly prescribed GLP-1RAs had higher rates of obesity (69.4% vs. 45.7%). This data indicates that clinicians are prescribing GLP-1RAs to help manage obesity in T1D patients, as weight management is a critical component of diabetes care.   The percentage of the T1D population prescribed GLP-1RAs increased significantly, from 0.3% in 2010 to 6.6% by 2023. The percentage prescribed SGLT2 inhibitors rose from 0.1% in 2013 to 2.4% by 2023. Overall, the percentage of T1D patients prescribed either of these medications increased from 0.7% to 8.3% during this period.     Results of the study suggest that despite regulatory concerns, off-label use of GLP-1RAs and SGLT2 inhibitors in T1D continues to grow primarily due to their cardiorenal and weight management benefits.   "Prospective studies on the efficacy and safety of GLP-1RAs or SGLT2 inhibitors in the T1D population are needed," the Research Letter concludes, "Before such evidence becomes available, caution should be exercised when prescribing these treatments to individuals with T1D."   https://medicalxpress.com/news/2024-10-glucose-lowering-drugs-diabetes-patients.html XX More good islet transplant news.. from Eledon Pharmaceuticals and University of Chicago. These are potentially the first human cases of insulin independence achieved using a transplant of insulin-producing islet cells in combination with its experimental immunosuppressant drug. The first two subjects achieved insulin independence and normal hemoglobin A1C (HbA1c) levels, a measure of average blood glucose, post-transplant. The third subject, who recently received an islet transplant, decreased insulin use by more than 60% three days following the procedure and continues on an insulin independence trajectory. Some of the funding for this study comes from Breakthrough T1D. https://www.globenewswire.com/news-release/2024/10/29/2970713/0/en/Eledon-Pharmaceuticals-Announces-Positive-Initial-Data-from-Subjects-with-Type-1-Diabetes-Treated-with-Tegoprubart-as-Part-of-an-Immunosuppression-Regimen-Following-Islet-Transplan.html XX   Semaglutide may reduce Alzheimer's risk in type 2 diabetes patients, with research suggesting significant protective benefits compared to other diabetes drugs. published in Alzheimer's & Dementia: The Journal of the Alzheimer's Association, the study suggests that T2D patients taking semaglutide had a significantly lower risk of developing Alzheimer's. This effect was observed consistently across various subgroups, including differences in obesity status, gender, and age. Semaglutide, which acts on glucagon-like peptide receptors (GLP-1R) to curb hunger and regulate blood sugar in T2D, is also the active component in the diabetes and weight-loss drugs Wegovy and Ozempic. About 120,000 Americans die from Alzheimer's disease each year, with the disease listed as the seventh-leading cause of death nationally, according to the CDC. https://scitechdaily.com/alzheimers-breakthrough-popular-diabetes-drug-ozempic-linked-to-much-lower-risk/ XX   XX Edgepark commercial XX Apple's non invasive blood glucose monitoring rumors are back. But this sounds like just software.. no watch or hardware. According to the report, Apple doesn't currently have plans to release the app, but may integrate the technology into its future health products. The app could reportedly show consumers how certain foods impact their blood sugar levels, based on measurements taken by existing blood sugar monitoring devices. One report says apple is exploring uses for blood sugar data and what tools they could create for consumers as a result. Latterly, he reports testing on the app has been paused, but says the tests could pave the way for better food tracking on Apple's own health software or better third-party glucose tracking integration. https://www.techradar.com/health-fitness/apple-is-testing-a-new-blood-sugar-product-but-its-not-the-apple-watch-update-weve-been-waiting-for XX And finally, it's diabetes awareness month. Please follow on social – I'll be doing a few things but mostly I think this month is great to educate the general public.. every month is diabetes month for this community. XX Join us again soon!

Medtronic and Abbott Join Forces: Groundbreaking CGM Partnership for Diabetes Care In this episode of 'Diabetics Doing Things,' we delve into the surprising partnership between industry giants Medtronic and Abbott. On August 7th, they announced their collaboration on a Continuous Glucose Monitoring (CGM) system, combining Abbott's advanced Freestyle Libre 3 technology with Medtronic's insulin delivery devices. We discuss the press releases from both companies, the strategic alignment that led to this partnership, and hear insights from Ali Dianaty, Senior VP at Medtronic Diabetes, and Dr. Anila Bindal, Associate Medical Director at Abbott's Diabetes Care. This episode covers the potential impact on diabetes care, market reactions, and what this means for patients globally. 00:00 Introduction and Episode Overview 00:18 Breaking News: Medtronic and Abbott Partnership 00:53 Reading the Official Press Releases 04:47 Interview with Industry Experts 05:43 Impact on the Diabetes Community 10:14 Future Expectations and Patient Benefits 18:11 Closing Thoughts and Final Remarks

Medtronic and Abbott are joining forces – and we have questions. The announcement that Abbott will create a new CGM, based on the Freestyle Libre, exclusively for Medtronic comes just as Medtronic gets FDA approval for it's newest sensor. So why the team up? Why now? And what will all this look like for the person using these systems?  We're talking to both companies. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Find out more about Moms' Night Out - registration is open for Denver and Philadelphia! Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom  Edgepark Medical Supplies Check out VIVI Cap to protect your insulin from extreme temperatures Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Medtronic is focusing on prediction as the next frontier in heart disease management, utilizing artificial intelligence to reduce false positives in its insertable cardiac monitors. The company's cardiovascular diagnostics and services business leader emphasizes the time-saving benefits for clinicians. Additionally, diabetes device firm Embecta is considering a sale two years after spinning out of BD, while Dexcom shares have plunged due to a lower sales outlook. The FDA has sent warning letters to Chinese syringe manufacturers, and the top five medtech deals in the first half of 2024 include Johnson & Johnson's takeover of Shockwave Medical. Roche Diagnostics' base business has grown 9 percent in the first half of 2024, and Tricares has raised $50 million to trial a tricuspid heart valve replacement system.Sanofi's bet on immunology is starting to pay off, with analysts noting that the pipeline of immune system therapies is underappreciated by investors. Pfizer's hemophilia gene therapy has shown positive results in late-stage studies, but questions remain about long-term potential. A startup led by former J&J executives, Third Arc Bio, raised $165 million for cancer and immune disease drugs. The US government declined to clear Bluebird Fertility Support for Zynteglo patients, and the GLP-1 drug race is heating up as pharma companies compete in the obesity market. The biopharma industry is evolving rapidly, with advancements in cell therapy and personalized cancer treatments.Steward Health System failed to attract qualified bidders during the first round of hospital sales in Ohio and Pennsylvania. Humana's CenterWell will open 23 primary care clinics in Walmart stores, while CMS is cracking down on ACA brokers to prevent unauthorized plan switching. AI is being used to power clinical trials and improve patient answer rates in healthcare organizations. The text also highlights stories from other publications, including the challenges faced by hospitals in non-Medicaid expansion states and the impact of Medicaid on insurers during the pandemic.Dexcom shares plunged due to a lower sales outlook, Abbott recalled Freestyle Libre 3 sensors for incorrect glucose readings, and a study found that AI's expert-level image analysis can be flawed. Edwards spent $1.2 billion on 2 heart device firms, Inspire Medical's COO is leaving for a CEO role at another company. Abbott stated that the sensor recall may affect less than 1% of users in the U.S. Researchers discovered that AI can generate expert-level image analysis with flawed reasoning. Edwards reported a slowdown in its core business, causing share prices to drop.Bristol Myers had a strong week of pharma earnings, with all five large pharmaceutical companies reporting raised profit or revenue guidance. Roche plans to move quickly with differentiated obesity drugs. Leqembi was voted down by European regulators, but Eisai plans to appeal. Two biotechs cut staff, while Abbvie weathers biosimilar threats. Sanofi's immunology pipeline is starting to pay off. The pharma industry is racing to develop GLP-1 drugs for obesity treatment.Gilead's $4.3 billion acquisition of Cymabay Therapeutics will face a significant test next month when the FDA decides on their autoimmune disease drug, Seladelpar. The treatment targets primary biliary cholangitis, a liver disease with no cure. Positive interim results have shown improvements in liver injury markers and reduced inflammation. Similarly, Citius Pharmaceuticals awaits an FDA decision on their rare blood cancer drug, Lymphir, with CEO Leonard Mazur personally investing $22.5 million in the company.The text discusses various marketing campaigns and initiatives, including Hyundai's shift to more emotional advertising for the Summer Olympics, Palo Alto Networks equipping Keanu Reeves with AI-powered weapons for a

@syde's final test on Glucose monitor FreeStyle Libre 3 System NewsIs our infrastructure too vulnerable? CrowdStrike blames test software for taking down 8.5 million Windows machinesCrowdStrike global outage to cost US Fortune 500 companies $5.4bn Introducing Llama 3.1: Our most capable models to dateIreland's datacentres overtake electricity use of all urban homes combinedGoogle Is No Longer Claiming to Be Carbon Neutral - Bloomberg GOOD READ: The AI summer by Benedikt Evans Has the silicon valley turned RED? Andreessen Horowitz co-founders explain why they're supporting TrumpHow a Network of Tech Billionaires Helped J.D. Vance Leap Into PowerAll in Podcast - conversation with President TrumpWashington's most powerful interests don't know whether to cheer Harris — or dread her Switzerland now requires all government software to be open source Inspiration#AUDIOBOOK :: Alexander the Great and the Macedonian Empire#DOCUMENTARY :: The Fantastic Mr Feynman #PODCAST :: Generation DIYSe libérer de la fatigue, profiter de la vie avec Léonard Anthony (Métamorphose)Alimentation, microbiote et santé mentale - Dialogue avec Dr Guillaume Fond (Dialogue de Fabrice Midal )#QUOTE :: “Old George Orwell got it backward. Big Brother isn't watching. He's singing and dancing. ... Big Brother's busy holding your attention every moment you're awake. He's making sure you're always distracted." Chuck Palahniuk Hébergé par Acast. Visitez acast.com/privacy pour plus d'informations.

Amazon vs Temu and Shein: Amazon plan to launch a discount shopping section would appeal to mainland Chinese suppliers with pricing flexibility, but competing with Temu and Shein in selling low-priced merchandise will not be easy, according to analysts.We surveyed 4,000 people across the US, UK, Australia, and Canada to learn more about how they shop online and what they think about major global and Chinese marketplaces like Amazon, Etsy, AliExpress, as well as newer Chinese players like Temu and Shein.Teams en Europe: EU charges Microsoft with antitrust violations over Teams VE:Volkswagen Will Invest Up to $5 Billion in EV Maker Rivian - The New York TimesTesla delivered fewer vehicles to customers for the second quarter in a row - The VergeAs Tesla slows, the bigger threat to BYD is home grownHeat pumps with thermal batteries - by David Roberts Inspiration#HEALTH :: @syde's test with glucose monitor FreeStyle Libre 3 System #BOOK :: La Méthode Glucose Goddess - Le programme scientifique de 4 semaines pour réduire vos fringales, retrouver votre énergie et vous sentir en pleine forme par Jessie Inchauspé#PODCAST :: Dan Carlin's Hardcore History Twilight of the AesirLE SPORT COMME GUIDE DE VIE AVEC THIERRY MARX par la Fondation Sports for Life #QUOTE :: “What you seek is seeking you.” Rumi Hébergé par Acast. Visitez acast.com/privacy pour plus d'informations.

It's In the News! A look at the top diabetes stories and headlines happening now. Top stories this week: Dexcom goes Direct to Watch in the US, Abbott gets FDA okay for its OTC CGM, new study about metformin during pregnancy, an update on semaglutides, JDRF changes its name, and more! Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom  Edgepark Medical Supplies Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens  Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links:   Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX In the news is brought to you by Edgepark simplify your diabetes journey with Edgepark XX Our top story this week – some CGM news… Dexcom announces Direct to Watch is here in the US. From the release: Using its own dedicated Bluetooth connection, Dexcom G7 sends glucose information and personalized alerts right to a user's Apple Watch. Dexcom G7 is the only CGM system that can display glucose on multiple devices simultaneously and independently, including on a smartphone, smart watch, receiver or connected automated insulin delivery system.‡ Apple products are built with strong privacy protections and users have control over their data in the Health app. (If you like to keep track of these things, we are just over 7 years since the official announcement this was going to happen) XX FDA approves Abbot's over-the-counter continuous glucose monitoring system. It's called Lingo and comes a couple of months after Dexcom won clearance for its Stelo over-the-counter CGM. Abbott has been selling Lingo in the UK as more of a lifestyle device – not aimed at people with diabetes. They call it a consumer biowearable designed to help people make decisions about their overall health and wellness; Lingo is not intended for use in diagnosis, treatment or management of a disease or medical condition. No word yet on exactly what kind of app they'll launch here in the US or if it will be marketed toward people with diabetes like the Libre currently is.. just as an OTC option. While it seems like the same hardware, the company has not confirmed that. https://www.drugdeliverybusiness.com/abbott-wins-fda-clearance-for-its-lingo-otc-glucose-monitor/ XX New study looking at the use of continuous glucose monitors (CGMs by rural children and adolescents living with type 1 diabetes. Previous studies examining the use of CGMs by children relied on prescription records to identify use of these devices, but just because someone is prescribed a CGM does not mean that they use one; barriers such as cost can stand in the way. this study instead identified use of these devices according to billing codes for the interpretation of CGM readings by the provider. The results unearthed a sizeable disparity. Those living in rural areas were significantly less likely to use a CGM than those in urban areas, even after adjusting for sex, race or ethnicity and insurance type. Specifically, compared with youth living in urban areas, the use of CGMs was 31% lower for children and adolescents living in small rural towns, and 49% lower for those living in isolated rural towns. The gap between rural and urban patients persisted across the four years of the study, even as the use of CGMs increased for all patient types during this time. These results are also relevant to people with type 2 diabetes who require insulin, Tilden said. The results also revealed that non-White patients, those who had public insurance and patients who lived in areas with a higher NPI all were less likely to use CGMs. More research is needed to explore the reasons for these disparities, but Tilden said they likely are a function of such issues as cost, reduced internet access, which CGMs require to relay their data, and distance from clinics and Medicaid-contracted pharmacies.   The next step is figuring out how to eliminate those disparities. These researchers are seeking funding to design an intervention that uses telemedicine and partners with a network of 35 clinics across Kansas to deliver specialty care to diabetes patients in rural areas.   https://www.kumc.edu/about/news/news-archive/diabetes-monitoring-disparities.html XX Metformin is just as safe to use during pregnancy to treat type 2 diabetes as insulin. The study, which hasn't been published yet in a peer-reviewed journal, tracked health data and potential long-term side effects of using metformin during pregnancy for up to 11 years postpartum. While today's popular GLP-1 medications, such as Ozempic, are not approved yet for use during pregnancy, metformin and insulin have been used during pregnancy for decades. https://www.medicalnewstoday.com/articles/metformin-may-be-as-safe-as-insulin-to-treat-diabetes-during-pregnancy XX Once weekly basal insulin is a no go from an FDA advisory panel. They found the potential benefits of the investigational once-weekly basal insulin analog icodec (Novo Nordisk) don't outweigh the increased risk for hypoglycemia in people with type 1 diabetes. We've been following this for a long time. Most of the trials here have been in people with type 2 – and the FDA hasn't publicly raised concerns about efficacy and safety seen in any of those trials. But the type 1 trial found a significant increase in serious or severe hypoglycemia with icodec compared with degludec (4.66 vs 1.0 events per 100 patient-years; 14 events in nine patients versus three in three patients), with the greatest incidence in the icodec group on days 2-4 after injection. None of the events resulted in treatment discontinuation or study withdrawal. This doesn't mean the FDA can't approve the drug – and the panel mentioned that they hope the FDA would work with Novo Nordisk to – quote - make sure that if this is approved there are as many guardrails as possible to make sure we don't harm people with type 1 diabetes." https://www.medscape.com/viewarticle/advisory-panel-votes-against-once-weekly-insulin-type-1-2024a10009we XX The shortage of Ozempic and Mounjaro continues… with some doctors offering advice of what to do if you can't fill your prescription. Health care company Ro recently launched a public crowd-sourced shortage tracker to help patients. The company says they also share the patient-reported shortages to the FDA. Chae says some patients could discuss with their doctor off-label use of other medications, like liraglutide injections (such as Trulicity, for example), depending on their preexisting conditions. Patients may also consider trying compounded semaglutide. Compounded drugs are made to order in local pharmacies, but Chae says be wary of them: Because of their bespoke nature, the drugs' safety isn't regulated by the FDA. “The state of Mississippi, North Carolina and West Virginia have banned these compounded drugs,” he said. https://www.scrippsnews.com/health/popular-diet-and-diabetes-drugs-in-short-supply-as-demand-surges XX Commercial XX Big news from JDRF – they've changed their name to "Breakthrough T1D." Here's the statement: "Breakthrough T1D was selected following a rigorous, data-informed process because it more accurately conveys the nonprofit's ability to connect with and work on behalf of the entire type 1 diabetes community," The median age for a person living with T1D worldwide is 37 years. Only about one in five are aged 20 years or younger, two thirds are aged 20-64 years, and another one in five are aged 65 years or older.   The organization was founded in 1970 by parents of children with T1D and was originally called the "Juvenile Diabetes Foundation." The "research" part was added in 2012 to reflect that aspect of its mission. We will have much more on this next week – Tuesday's episode is an interview with JDRF. Oops with Breakthrough T1D. https://www.medscape.com/viewarticle/type-1-diabetes-group-grows-jdrf-now-breakthrough-t1d-2024a1000afr XX Android users – heads up! The FDA has approved a hybrid, closed-loop, insulin-delivery Android app. In May, CamDiab, revealed that the CamAPS FX had received approval. CamAPS FX is approved for people with type 1 diabetes who are two years of age or older, including those who are pregnant.   CamAPS FX works in unison with the FreeStyle Libre 3 and the Dexcom G6 to produce a hybrid, closed-loop system that is compatible with the Ypsomed mylife YpsoPump. The app and those pumps are already approved in several other countries. You may recall that the YspoPump had a partnership with Lilly to bring that pump to the US – but that deal died in 2022. Yspomed is still moving forward to get FDA approval for their pump. https://beyondtype1.org/fda-approves-camaps-fx-hybrid-closed-loop-insulin-delivery-app/?fbclid=IwZXh0bgNhZW0CMTEAAR137RhLAt2GfIJ_BBYMrhU2R-maQ0EQmwOFhPfKN9iCnG2BKWY6dEB0sTk_aem_ATLPk1xWOnLNzPz7LvYINbTdCVMZk7pcRmma2pgG5MIo0OfinomTSgjsTsTpW_fE6GNVRnScZS6UGzaTvP1SewNW XX Driven by payments for diabetes treatments — especially insulin — prescription drugs for metabolic diseases now make up nearly one quarter of total national pharmaceutical spending, reported a study of spending trends by therapeutic class. The detailed examination of a decade's worth of US drug spending also found changes in who pays for the medicines, with an overall drop in out-of-pocket costs, except in the metabolic disease category. The findings add to concerns about the costs of US diabetes treatments. Annual US spending on diabetes medicines surged from $27.2 billion in 2011 to $89.2 billion in 2020,  according to this paper was published online in Research in Social and Administrative Pharmacy. In the same period, total annual pharmaceutical spending rose at a far slower rate. Yet much of the persistent gain in the cost of diabetes treatments in this same period was due to a decades-old drug, insulin, a cornerstone of diabetes care. https://www.medscape.com/viewarticle/study-raises-concerns-about-rising-cost-diabetes-meds-2024a1000a8e XX The number of people aged over 16 with insulin-dependent diabetes and eating disorder symptoms is as high as one in four, a study has revealed. Researchers from the University of Eastern Finland examined the findings from 45 past studies, looking at data from almost 11,600 people with insulin-dependent diabetes. They say that understanding the extent of the issue is the first step in developing treatment pathways, citing Finland as an example of a country which does not have care pathways for people with both diabetes and eating disorders. Of course, neither does the US. Typical eating disorder symptoms include restricting food intake and binge eating. Symptoms particular to insulin-dependent diabetes include insulin omission, which is when individuals restrict or skip insulin doses due to fears of putting on weight. The prevalence of eating disorder symptoms was higher in women than in men, a finding previously made in young people too. The age of an individual was not found to be a factor, with eating disorders occurring regardless of age group. https://www.diabetes.co.uk/news/2024/jun/1-in-4-people-with-insulin-dependent-diabetes-have-eating-disorder-symptoms-research-shows.html XX Congrats to Kate Farnsworth who recently won Diabetes Action Canada Catalyst for Change award. Many of you know Kate from the early DIY days.. Kate Farnsworth is the patient partner co-lead for the Innovations in Type-1 Diabetes Program. Kate has been heavily involved in the Do-It-Yourself #wearenotwaiting movement since her daughter Sydney was diagnosed with type 1 diabetes at the age of 8. With a background in information technology and graphic design, Kate has lent her skillset to developing diabetes watch faces for remote monitoring used by patients worldwide. Kate has created an online patient-driven support community for people who are exploring DIY closed-loop solutions and continues to advocate for all people with diabetes to have access to the best tools to manage their diabetes. Very nice to see this award go to someone very well deserved. XX Join us again soon!

Roy Morgan, CEO of Eagle Medical, shares his unique journey in the MedTech industry, starting from a pivotal one-question interview in 1997 that set the trajectory of his career. He reflects on his experiences in leading groundbreaking projects, emphasizing his deep-seated desire to improve and save lives. Roy's approach to leadership is both inspiring and intellectual, demonstrating a commitment to excellence and a profound understanding of the impact of his work.  Guest link: www.eaglemed.com Charity supported: Sleep in Heavenly Peace Interested in being a guest on the show or have feedback to share? Email us at podcast@velentium.com.  PRODUCTION CREDITS Host: Lindsey Dinneen Editing: Marketing Wise Producer: Velentium   EPISODE TRANSCRIPT Episode 030 - Roy Morgan [00:00:00] Lindsey Dinneen: Hi, I'm Lindsey and I'm talking with MedTech industry leaders on how they change lives for a better world. [00:00:09] Diane Bouis: The inventions and technologies are fascinating and so are the people who work with them. [00:00:15] Frank Jaskulke: There was a period of time where I realized, fundamentally, my job was to go hang out with really smart people that are saving lives and then do work that would help them save more lives. [00:00:28] Diane Bouis: I got into the business to save lives and it is incredibly motivating to work with people who are in that same business, saving or improving lives. [00:00:38] Duane Mancini: What better industry than where I get to wake up every day and just save people's lives. [00:00:42] Lindsey Dinneen: These are extraordinary people doing extraordinary work, and this is The Leading Difference. [00:00:51] Hello, and welcome back to The Leading Difference podcast. I'm your host Lindsey, and I'm so excited to be speaking with my guest today, Roy Morgan. Roy has had a distinguished career at multiple medtech corporations. His experience includes team building, platform strategy, intellectual property filings, project management, budgeting, and scheduling. His project design and engineering skills are highly sought after in the medical device field, and Roy has a BS in Mechanical Engineering, a BA in Semiotics from Brown University, as well as a degree in project management from the University of California at Berkeley. Roy currently serves as the CEO of EagleMedical. [00:01:32] Roy, thank you so much for being here. [00:01:34] Roy Morgan: Well, it's wonderful to be here, and thanks for having me. [00:01:36] Lindsey Dinneen: Course. Well, I would love if you don't mind starting off by sharing a little bit about yourself and your background and what led you to MedTech. [00:01:45] Roy Morgan: Sure. So, my journey into medtech started in 1997 with a one question interview phone call. And it was an amazing moment in my career. I'll never forget it because it was only one question, and the question was, "Can you invent?" And I'll never forget it because I'd never heard that question asked before. You know, looking back now on a 30 plus year history in med device, I think I answered the question right. But some days I'm still not sure. [00:02:15] I started out after that working for the Stryker endoscopy division of the Stryker corporation, was the lead innovator commercializer of their, I guess it's currently called the Crossfire Electrosurgical System. So I drove, you know, those things into market. I worked on their sports med team for a while, went on from there to work for some small startups doing other RF innovations in you know, tissue excision spaces, treatment spaces, then did some interesting work for Abbott diabetes care that launched I think people can see that now on television, it's called Freestyle Libre, it was originally known as Navigator. I was part of that development team in the early 2000s that got that off the ground and into the market [00:03:07] Subsequent to that, went to do additional in vitro diagnostics and diabetes work for some startups in florida And then came back to the Bay Area, and found myself kind of wanting to do something a little bit different, and chose to work with a company called Eagle Medical to drive sterilization, packaging, and innovations in assembly technique and you know, speed to market from the last operations process standpoint. And that's where I find myself today. [00:03:42] Lindsey Dinneen: Very nice. Well, thank you for sharing a little bit about your background. Did you always think that you might be an inventor or was this something that kind of came about over time? [00:03:53] Roy Morgan: Well, you know, it's interesting. That question, if you can imagine yourself taking a phone call and thinking like the recruiter building this up as like, "Wow, this is the next greatest company since, you know, I don't know, Johnson and Johnson" or something like that. And you feel all this pressure. And then it's one question. And I can't tell you exactly how I answered it. It was something to the effect of, "Well, I can't be 100 percent certain, but I believe with every cell of my being that I can do it." And I guess it was good enough to get the next round of interviews. It worked out. [00:04:29] And today I'm blessed to have been part of just an amazing industry. The things that I have been able to participate in, that I've seen done that are going on today, and that we continually, through Eagle, help produce for the greater global community, just amaze me. It's remarkable what we are able to do. It's even more remarkable the things that we're targeting to do in the coming years. [00:04:56] And so all of that just kind of makes me think: I hope I can continue to invent and do things. I've been blessed and fortunate to have more than a few patents to my name at this point. So I think there's some truth to the answer I gave, or at least I, you know, I kidded myself into believing it and it worked out. [00:05:15] Lindsey Dinneen: Well, yeah, you believe it and then you do it, right? So hey, you're just... [00:05:19] Roy Morgan: There's lots of phrases for that. I won't use them here, but you know, it worked out is what I'll say. [00:05:25] Lindsey Dinneen: Fantastic. Well, if you wouldn't mind sharing just a little bit about your work today with Eagle and just share a little bit about your heart behind it. I know you're very missions and values driven, and I would love to hear more about that too. [00:05:39] Roy Morgan: Sure. I'll start with our why, because I think that's the biggest and most important thing to understand. Our mission here at Eagle is to provide just the absolute best quality of service to our customer base, and our customer base comes in layers. But I always try diligently to remind our staff at every level in the company that the most important layer of customer that we have is the end recipient of the products that we package here. [00:06:15] They, as I like to tell them, they don't get a say. They're under anesthesia. They're unconscious. They can't see the quality of our work. They don't know, perhaps, even that it's part of the surgical process that there'll be receiving on any given day, of course, there's an implicit faith in our system that these products will be delivered in sterile conditions, that they are able to provide all of the benefit that surgeons, clinicians and support staff say that they can, and because our patients don't get a say, we have to do it right every time, all the time, without exception. [00:06:56] And that's something that we really try to drive home here to, to everyone that works at Eagle. It's part of what we do, and the other thing that I remind people about is that everything that comes through our facility has UDIs and part numbers on them, but that's really a misnomer. Each and every product that comes through here really has a name on it. And that name could be a sister, a brother, father, mother, could be your own name. And so remembering that, I think, really brings home the importance of what we have to get right every day. [00:07:33] Lindsey Dinneen: Yeah. Yeah. And have you had any particular moments where it just really stood out to you as confirmation that you were in the right place at the right time in the right industry? This awareness of, "Oh, wow, yes, this is why I do what I do here." [00:07:51] Roy Morgan: Wow, that's a great question. It's I don't know that there's like one moment. There are strings of moments that, that I can piece together in my mind. Most of it I think comes down to something that's deep seated in myself that has to do with desire for spreading good health to everyone around me, and I think it's... how do I say this? It's really something that's almost unconscious for me. There's a desire to see healing in people. [00:08:28] Without going into it really in my own background, there's healing that's had to go on for me and others in my family that are important things to support, to encourage, and to help along in the world. And those I think are, they're just very powerful beliefs for me. And so the moments in my career that kind of lend themselves to that, have been moments in operating theater with patients that are conscious. [00:08:58] Without getting too much into it, some very high profile athletes that have thanked me for the innovations that we brought into that operating theater that would enable them to continue their championship level sports endeavors. So it's about giving people a continued opportunity in life to do what they love to do to restore the life that they want and to have second chances when injury or misfortune might befall us, as it does all of us. [00:09:30] So I think those moments really stand out in my mind as, "wow moments" where, you know, you may not be expecting it, you, it catches you off guard and it gives you a little bit of introspection about your own why. Why am I doing this? What's my mission? So, yeah, those are the kinds of things that, that count. [00:09:51] Lindsey Dinneen: Yeah, and I love the way that you put it earlier where you were saying how-- and I think it's very human nature-- we get into the nitty gritty of the details and, and sometimes it does feel like, well, it's just, it's a component, it's a part number, it's whatever. And I love the way you put it about how actually those are, they get assigned to people. Those are humans who are affected by each and every one of the things you produce. And I love your emphasis in general, just listening to you speak, your care for human life and bettering it and helping the next generation. [00:10:26] So I just want to say thank you for your perspective, because it's easy to lose sight of that when you're having to do such detailed work, I think, and I love that you continue to remind the folks that work with you and yourself, I assume, too, about how important this is, and it's, it's not just another day for somebody who's affected directly by what you're doing. And I think that's pretty cool. [00:10:49] Roy Morgan: Yeah. Yes. Thank you. It's really my honor to serve in this role. [00:10:54] Lindsey Dinneen: Yeah. Well, what are you excited about next as your company continues to grow, you continue to invent and innovate. What's exciting for you? [00:11:03] Roy Morgan: Well, so, you know in our industry, the past couple of years with the pandemic and other industry related challenges have made it a difficult time for a lot of med device manufacturing . Just to, to name a few, you've had supply chains that have gone upside down and sideways and every other way you can imagine. You've seen sterilization modalities come under intense environmental pressure, forcing closures throughout the industry of certain types of modalities, and putting pressure on the balance of the system to rise to the occasion and meet the excess demands, which of course, something like a pandemic raises to an entirely new level. I don't know if we understood it, prior to 2020, in the visceral manner that I think we do now that a strong healthcare supply chain, a strong healthcare technology sector is really a matter of national security. It's really a matter of being able to sustain our population and sustain our society at a level that is functional. [00:12:14] I think the events of the past two years have highlighted for everyone that importance. So, I speak about those things in terms of how it's raised awareness. The excitement that it creates within me for the coming years is that I see tremendous innovation in how we're going to make things more resilient, how we're going to make them more capable, more scalable. And here at Eagle, what we're doing specifically, is implementing new digital transformations of this last operations process workflow so that we are able to spool up to demand levels that might seem insane. But to do it without breaking the machine, if you will. [00:13:02] And I think a lot of a lot of companies out there, a lot of my compatriots that I speak to, CEOs across the industry, I hear the same echoes that, wow, there was just so much that had to be done that it was very difficult and nearly broke us to try and reach those levels of production. So I think building those systems now and putting those in place for us, really is exciting to look at the future to say, "Okay, we'll be much more ready next time around." [00:13:32] Lindsey Dinneen: Yeah, I mean, fingers crossed and all, there won't be that same. But I love that you are actively working towards it because I think you're absolutely right. It took so many people completely off guard and without having come up with a way to handle it ahead of time, it was very difficult for many people. So I love that you're going ahead and putting those systems in place to be prepared and, tackle it head on in the future. [00:14:00] Roy Morgan: One, you know, one of the things that we're doing just as part of evolutionary innovation in the packaging space, we've developed a new system that's called the "PATH System." It's our Packaging Accelerated Timeline Help. And what it is, it really represents the first step of digital transformation of packaging validation. Traditionally packaging validations have been thought of as the rigor that terminally sterilized device has to be subjected to, to get all the way through distribution to actual operating theater, and it is and has been so for many decades. But, we have continually been testing the same types of packaging for decades. [00:14:43] We, Eagle, just ourselves within our own production database, we've got millions of test data points that we can mine and use to our advantage. And in fact, we've done that. And what we've created is our own engineered proxy device that we validated inside of a packaging solution. So, PATH is really, I call it a time machine because what you're buying is not a pre validated sealed package that contains nothing but air. You're getting a full digital data package of a validated proxy device. [00:15:21] It can be adopted as a worst case for any product family that's out there. The short story is, you're buying time, which helps a lot of companies out there that are trying to bring life altering technologies to market. They can save that time and that money, of course, because they both go hand in hand, getting to market sooner and being able to deliver that life altering technology to potential patients so they can benefit from it. [00:15:47] We saw this as a natural innovation in the space of time compression, of the utilization of massive amounts of data in the historical canon that we have, and that other companies also have. So really, it just kind of made sense for us to move forward with it. It's now available. And we're seeing lots of interest and we expect to see a few companies take advantage of it in 2024 to get to market much more rapidly. [00:16:12] Lindsey Dinneen: So exciting. Oh my goodness. Yeah. Thank you for sharing about that. I'm excited to look into it a little bit more too, but it's great to see all the innovation coming out of this space and keeps the hope very much alive that there continues to be passion and innovation moving forward. So, you know, throughout your career, you've held multiple leadership roles, of course, and I'm wondering how you view leadership. What is your own leadership style or philosophy and what's your advice for someone who might be looking to get into a more of a leadership role in the medtech industry for themselves? [00:16:50] Roy Morgan: Sure. I'd say my leadership style is, I lead with inspiration and I follow with intellect. So it's pretty straightforward, but not easy to do. The inspiration is, I think, been popularized lately by Simon Sinek, who talks about start with "why." Well, that's what it is. Inspiration is the why. The intellect, that's what I call the mechanics of how to get it done. And that's really how I've gone throughout my career in tackling the various leadership roles that I have had the privilege of being a part of. [00:17:30] I guess what I would say is to anyone looking and thinking about how to be an effective leader, it's a, it's as much an exercise in vulnerability as it is an exercise in your commitment to your own mission. You've got to know what that is. If you're going to be a leader, you want to be a leader in some particular endeavor, it's going to require a personal commitment to believe in that, to move toward it, and to live up to it. You're going to lead by example, which is generally the best way. But you're going to put your own success in the hands of others. [00:18:16] I can't say that as a leader, the success is all mine, it's not. I've worked with some of the most amazing teams, the most talented engineers, the most amazing people who help make things happen in a way that leads to that success. And so that's the exercise in vulnerability. I often tell people being a leader means that you're willing to underwrite failure after failure without loss of enthusiasm. [00:18:43] Lindsey Dinneen: Yes. [00:18:45] Roy Morgan: And if you're, you know, if you're able to do that you'll get there. So. [00:18:49] Lindsey Dinneen: Yeah. Thank you so much for that advice. I really appreciate your perspective too. Yeah. And so how do you see that play out especially nowadays where, you're in this obviously top leadership role, and one of the things that you are so passionate about is this sense of mission and core values and why we're doing what we're doing. And so I'm wondering, what are some ways that you have found to be effective in shaping culture to reflect the core values and help ensure that alignment, because I know sometimes, it's lovely to write those statements and we believe in them and we want them to be true, but it can be hard in the day to day operations when things get tough and difficult decisions have to be made to really adhere to them. So I'm wondering, how do you go about that particular component of leadership? [00:19:43] Roy Morgan: You've caught me at an opportune juncture in my career. Let me give you the setup and then I'll tell you what's going on. For the past 20 plus, 30, almost 30 years now, I guess, yeah, 30 years, I have used a performance management system, a goal system, which most people are familiar with, that I'll work with individual team members, my direct reports and their sub teams, et cetera, to establish a set of goals. That's worked very well. It's been successful and has provided a great amount of accomplishment over that time period. [00:20:17] But recently I felt like I was getting stuck in a rut, that the goal system as effective as it is has become-- I'm not sure what the best way to put it-- other leaders out there who go through this sort of self check in or appraisal, if you will, will understand what I'm getting at. You're just wondering if, "Gosh, I haven't innovated myself in a long time." And I would say that this is the other challenging thing about being a leader: if you let yourself get stuck in a rut, you develop complacency. Just like teams, just like company, it all happens, but it can happen to you. And I think in 2023, I took a look in the mirror and I said, "You know what? I'm feeling a little complacent. I'm feeling a little bit like this goal system is just my go to thing. I've done it for 30 years." [00:21:09] And so this year, I am trying something very different. We're trying the Four Disciplines of Execution, the 4DX approach, to how we're going to run our team goals. So, people out there who are familiar with it will know what it is. I'm not going to go, it's not going to go into the details of it here. But Lindsey, what I'll tell you is, for me, it's terrifying at the outset because it feels like I'm taking my hand off the wheel. I'm entrusting my teams to develop their goal set, to set their timing, to set their commitments. [00:21:50] Sure, I took part in setting the what they call the "WIG," the wildly important goal for the year, right? But I didn't set it by myself. I had to call the team in and say, "Look, guys, this is where we are. This is the struggles we're going through. This is what we want to achieve going forward. Is this the right goal for us to focus on?" I created a proto goal, but it was modified and I was okay with that. So, it's basically a starting line, a finish line and a deadline, right? [00:22:21] And so we did that. They changed it. It's now created and I'm uncomfortable. I'm in that, I'm in that gray space of uncomfortableness where I'm trusting that the system, which has many successful reports is going to work for us in the same way. It's knocking me out of my comfort zone. And I did that to myself on purpose. I'm doing this because, for me, I know that's a growth zone. I'm going to have to stretch. I'm going to have to grow. I'm going to have to think differently moving forward. It's terrifying. [00:23:00] And I would say to other leaders out there, this is what you have to do. This is what you have to do to achieve growth, having mentors, having other inputs, those are valuable, and they work for me too. But really this is a question of courage. It's a question of courage. You have to step up to the plate. I'm taking a swing. I'm hoping I hit the ball and if I do, I hope it goes over the fence. [00:23:28] Lindsey Dinneen: I love it. Thank you. Thank you for sharing that. I I really appreciate first of all, you being willing to talk about that because it is uncomfortable when you're going through a growth season maybe whether it's your choice or not, but even more so, when it's your choice and you're going, "I'm doing this because it's like you know taking your daily vitamins or whatever, maybe something you don't love, but you know it's for your benefit in the long run," and, but I understand that curve of, "Oh boy, this is, there's a lot of change and we're gonna, we're gonna see how it goes." But I commend you for that. I really do. And I'm excited. I hope we get to check back in a year and all things, "Say, hey, how's it going?" [00:24:08] Roy Morgan: Great. Yes. I hope to have great reports for you. [00:24:11] Lindsey Dinneen: I love it. Well, that was great. I really appreciate that. Pivoting just a little bit for fun. Imagine someone were to offer you a million dollars to teach your masterclass on anything you want. What would you choose to teach and why? And also, it doesn't have to be in your industry. It can be, doesn't have to be. [00:24:31] Roy Morgan: Sure. I think for me it would be it would be about creativity. It would be about, it would be about how to organize your life to have creative moments at as many turns as you possibly can, because creativity in itself, people ascribe for whatever reason, I guess in Western culture, we talk about it as a, an element of productivity or an element that's woven into capitalism, if you will, in a way that I don't think it's necessarily-- no, in fact, I know this-- it's absolutely not meant to be that. [00:25:11] Creativity is a source of fun by and large at its core, at its absolute core. It's like being... How do I say this? Well, this happened to me the other day. I was out on my, my, on my bicycle and I came over this hilltop after a long, hard climb and I began this descent and it was it was so overpoweringly filled with joy, that for a moment, you forget what you're doing. You have to get back on task quick 'cause it's a mountain road and you don't wanna make mistakes. But in that moment, it's, it's just about the joy and the fun. [00:25:45] I think I would teach about that because there are so many, I guess, so many challenging moments in human life for so many people, that to have a structure to help themselves to bring themselves joy, well, that would be really rewarding. Yeah, so I think that would be what I would talk about: how those elements in, in my own life got me through some difficult periods and, saw me through to the other side. [00:26:26] Lindsey Dinneen: Yeah. I love that. [00:26:28] Roy Morgan: That would be it. [00:26:30] Lindsey Dinneen: I would totally take that masterclass. I'm all about creativity and joy, so, yeah. That sounds like a fabulous class to teach. How do you wish to be remembered after you leave this world? [00:26:41] Roy Morgan: Ooh, wow. That's, that's a question that combines both austerity and optimism in the same note. How would I like to be remembered? I guess if I had to put it in one sentence, as a song. I don't know, I don't know that, yeah, I don't know that song is fully written yet. [00:27:04] Lindsey Dinneen: Yeah. [00:27:06] Roy Morgan: Yeah, I think that's how. [00:27:07] Lindsey Dinneen: Okay. Now, would it be instrumental or would it be a lyric-ed song? [00:27:15] Roy Morgan: It would probably have few lyrics and it would be mostly music. [00:27:21] Lindsey Dinneen: Okay. I'm digging it. That's by far the most creative answer I've ever gotten for this question. So I I'm loving it. [00:27:29] Roy Morgan: Well, it's, there you go, creativity, right? [00:27:32] Lindsey Dinneen: There you go. [00:27:33] Roy Morgan: That's what it's all about. [00:27:34] Lindsey Dinneen: Reoccurring theme. I love it. Yeah. And, and final question, what is one thing that makes you smile every time you see or think about it? [00:27:45] Roy Morgan: Oh, wow. One thing, there's so many things I'm lucky like that, that do that for me. I, well, the one thing that pops into my head right now is the sunrise. And I guess that, that kind of ties it in for me. I have this saying that I tell people, in fact, I was just doing a whole bunch of it here on New Year's Day. I say this all the time to myself and to others, "Well, here is another 365 chances to be great." [00:28:15] Lindsey Dinneen: Yeah. [00:28:16] Roy Morgan: So with each sunrise, a new chance to be great. [00:28:21] Lindsey Dinneen: Yes, and that's definitely a reason to smile. There's new hope every day. I love it. [00:28:28] Roy Morgan: May sound a little corny, but it works for me. [00:28:29] Lindsey Dinneen: I'm all about the corny when it works. Sometimes even just the corny for corny's sake. Let's be real. Yeah, well this has been an amazing conversation. I really appreciate you. I love the work that you're doing, but I especially resonate with and so value the emphasis that you put on remembering that what you're doing and the work that you're producing matters so much and it matters to humans and it's not just another part coming out. And so I just want to reiterate again how much I appreciate the way that you talk about that and the way that your company actively works to change lives for a better world. [00:29:09] So thank you for what you're doing and what you're bringing to the world. And I just really appreciate it. And we're excited to be making a donation on your behalf, as a thank you for your time today, to Sleep in Heavenly Peace, which provides beds for children who don't have any in the United States. So thank you for choosing that charity to support. And thank you again so much for being here. This has been a wonderful conversation. [00:29:36] Roy Morgan: It's been my pleasure, Lindsey, and I wish you and all your team there a wonderful 2024. [00:29:42] Lindsey Dinneen: Thank you. And thank you also to our listeners for tuning in. And if you're feeling as inspired as I am right now, I'd love it if you'd share this episode with a colleague or two, and we will catch you next time. [00:29:55] Ben Trombold: The Leading Difference is brought to you by Velentium. Velentium is a full-service CDMO with 100% in-house capability to design, develop, and manufacture medical devices from class two wearables to class three active implantable medical devices. Velentium specializes in active implantables, leads, programmers, and accessories across a wide range of indications, such as neuromodulation, deep brain stimulation, cardiac management, and diabetes management. Velentium's core competencies include electrical, firmware, and mechanical design, mobile apps, embedded cybersecurity, human factors and usability, automated test systems, systems engineering, and contract manufacturing. Velentium works with clients worldwide, from startups seeking funding to established Fortune 100 companies. Visit velentium.com to explore your next step in medical device development.

In this episode of AbbottTalks, Mahmood Kazemi, MD, Chief Medical Officer of Abbott's Diabetes Care business overviews the profound advancements in diabetes management over the past decade and discusses the evolution of treatments and technological innovations that have revolutionized how individuals with diabetes approach their condition. Further, Dr. Kazemi underscores the benefits of advancements such as the GLP-1 receptor agonists and medications that control glucose levels and offer cardiovascular and renal protection. He then elaborates on how Abbott's FreeStyle Libre continuous glucose monitoring (CGM) systems have significantly improved diabetes management. These systems provide real-time data, empowering individuals to customize their medication, diet, and activity levels with unprecedented precision. He also speaks to Abbott's ongoing and future work, including developing a state-of-the-art continuous glucose ketone monitoring (CGKM) sensor. This medical biowearable is designed to provide crucial early warning signs in Type 1 diabetes management, a significant step towards preventing dangerous complications and hospitalizations. Looking to the future, Kazemi anticipates a wider adoption of CGM across the diabetes community, including those with type 2 diabetes, and an increase in insurer coverage. Thank you to BMP Medical for sponsoring this episode of AbbottTalks! For more information on how BMP Medical works with medical device companies, visit www.bmpmedical.com Thank you for listening to the AbbottTalks Podcast. Tune in and subscribe to DeviceTalks on all major podcast channels to never miss an episode.

In this heartwarming episode of We Are T1D, Mike and Jack sit down with Maria, a familiar voice from the community who always engages with the podcast's wins and struggles. Maria, a healthcare assistant and a Type 1 diabetic, shares her story of diagnosis, which includes a surprising revelation of fruity breath leading to a DKA diagnosis, and the steep learning curve of managing insulin injections. As they delve into the intricacies of shift work with T1D, Maria reflects on the challenges and strategies she employs to keep her blood sugars in check amidst the unpredictable routine. The conversation takes a humorous turn with tales of injection mishaps, including the perils of biting off needle caps and more! Listeners are invited to join the banter as the trio discusses the pros and cons of different CGM sensors, the struggle to keep them adhered during sweaty gym sessions, and the surprising shortage of alcohol swabs that once accompanied the sensors. Maria also shares her approach to carb counting (or the lack thereof), the importance of considering future activities when dosing insulin, and the therapeutic effect of a well-timed hypo snack. The episode culminates with Maria's sage advice for those newly diagnosed with T1D, emphasizing the strength of the online community and the wealth of resources available. Follow The Podcast https://www.instagram.com/wearet1d Follow Mike https://www.instagram.com/t1d_mike Follow Jack https://www.instagram.com/t1d_jack Connect with Maria https://www.instagram.com/t1d_maria_greenwood Join the conversation at https://wearet1d.com Don't forget to Subscribe/Follow, Rate, and Review to be part of our vibrant T1D family. Share your stories, laugh along with ours, and let's navigate the ups and downs of T1D together. Stay strong, stay informed, and keep sharing those hypo stories with a side of ketchup (weighed or not)!

Strap in for an episode that takes you on an emotional roller coaster through the highs and lows of living with Type 1 Diabetes. Mike and Jack are your candid guides, sharing their personal wins, like Mike's wrap revelation and Jack's late-night McDonald's success, proving that with the right management, even fast food can be on the menu. But it's not all victories and happy meals. The duo gets real about the struggles that come with T1D, from emotional turmoil affecting blood sugar levels to the baffling absence of hypo symptoms. They dive into the complexities of managing diabetes amidst life's chaos, offering both solace and solidarity to anyone who's had one of those days where nothing seems to go right. Amidst the heartfelt discussions, there's plenty of classic Mike and Jack banter, complete with cat antics, gym aspirations, and a sea lion joke that might just have you groaning. And, as always, they tackle the misconceptions surrounding diabetes, calling out social media influencers and discussing the implications of potential school phone bans on diabetic students. This episode also serves up the "Guess the Carbs" challenge, inviting you to join in and test your counting skills alongside the hosts. So whether you're here for the deep dives, the laughs, or the community, "We Are T1D: Type 1 Diabetes" has something for everyone. - Follow The Podcast https://www.instagram.com/wearet1d - Follow Mike https://www.instagram.com/t1d_mike - Follow Jack https://www.instagram.com/t1d_jack - Share your journey and join the community at https://wearet1d.com Catch new episodes every Sunday and wednesday and don't forget to Subscribe/Follow, Rate, and Review to support the show and connect with the T1D family. Here's to finding strength, sharing experiences, and living boldly with Type 1 Diabetes. See you next episode! Keep fighting the good fight, and remember, you're not alone in this.

Welcome to the MassDevice Fast Five medtech news podcast, the show that keeps you up-to-date on the latest breakthroughs in medical technology. Here's what you need to know for today, February 8, 2024. Check out the show notes for links to the stories we discussed today at MassDevice.com/podcast. ShiraTronics completed its implantable migraine therapy pilot enrollment and set up its U.S. clinical study. Fast Five hosts Danielle Kirsh and Sean Whooley talk about the technology and what some of the data has shown so far. TAVR and Critical Care drove Edwards to its fourth-quarter sales beat. Hear more about the overall financial performance and how some of the individual segments performed. Nature Journal is raising questions about Neuralink's BCI study. Whooley explains some of the concerns and why they are important. Medtronic is touting the cost-effectiveness of Linq insertable cardiac monitors. The Fast Five hosts go over what the technology does and what data supported that claim. Insulet has integrated Abbott FreeStyle Libre 2 Plus into the Omnipod 5 technology in Europe. Learn more about the approval and why it's important for Abbott.

In this week's episode of We Are T1D: Type 1 Diabetes, Mike and Jack face off with a new challenge: to avoid saying the word "man" throughout the entire show. With a potential forfeit looming over their heads, the stakes are high, and the tension is palpable. Will they succeed or will they be left to the mercy of the infamous hat of consequences? Mike celebrates a monumental win with his latest HbA1c results, proudly sharing his journey from a 79 to a stellar 50, thanks to his trusty CGM. Jack, on the other hand, boasts a triple-night streak of stable blood sugars, attributing his success to a switch from late-night sweets to a healthier snack routine. But life with T1D isn't without its whoopsies, as Mike discovers when he forgets his insulin at home, leading to a frantic workday and a reminder of the importance of preparation. Jack struggles with the opposite problem, finding it difficult to wake up after nights of peaceful, undisturbed sleep due to well-managed levels. The "Guess the Carbs" segment returns with Mike and Jack putting their carb-counting skills to the test, revealing that even the best can be stumped by the hidden sugars in our meals. Listener wins and struggles are shared, offering a sense of community and support that resonates with anyone living with Type 1 Diabetes. From hypo-induced eye test hilarity to the unexpected synchronicity of medical appointments, this episode is a rollercoaster ride of emotions, humor, and the raw realities of managing a chronic condition. Join us for an episode that will have you laughing, nodding in agreement, and maybe even learning a thing or two about the royal family's mechanical skills. It's a reminder that while T1D is a part of life, it doesn't have to overshadow the joy and camaraderie found in shared experiences. Follow The Podcast https://www.instagram.com/wearet1d Follow Mike https://www.instagram.com/t1d_mike Follow Jack https://www.instagram.com/t1d_jack Get your wins on the podcast at https://wearet1d.com New episodes go out every Sunday! Don't forget to Subscribe/Follow, Rate, and Review to help others find the podcast and join the T1D community.  

It's In the News, a look at the top stories and headlines from the diabetes community happening now. Top stories this week: Vertex pauses their stem cell transplantation trials after a patient death, spray insulin is tested, learning more about Dexcom's sensor for type 2, measuring A1C through menstrual blood and more! Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom  Edgepark Medical Supplies Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens  Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcript: Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX In the news is brought to you by Edgepark simplify your diabetes journey with Edgepark XX Our top story this week… XX Vertex Pharmaceuticals, Inc. has paused a study of stem cell–derived, fully pancreatic islet cell replacement therapy (VX-880) following two patient deaths. Neither death is related to the therapy itself - called VX-880 – according to the company. Vertex says they plan to share full data soon. In the study that was paused, 14 patients with type 1 received infusions of VX-880 and standard immunosuppression. After 90 days, 13 of the patients have an A1C under 7 without using exogenous insulin. This was the study that made a big splash in the New York Times in late 2021 with the headline “A Cure for Type 1 Diabetes?” and featuring Brian Shelton among others. Shelton is one of the two patients who have died.   https://www.medscape.com/viewarticle/vertex-pauses-islet-cell-study-after-patient-deaths-2024a10000oe XX Early days but researchers in Norway are testing an insulin body spray. Patients squirt the insulin directly on to their inner forearm, where skin tends to be thinner, allowing easier absorption. Within minutes, it gets absorbed into the bloodstream. This joins other research on skin patches packed with micro-needles that punch tiny and reportedly painless holes in the skin to let insulin seep through. The spray contains insulin and propylene carbonate, a chemical often used in cosmetic skin creams to help them penetrate the outer layers of the skin. In this case, it's hoped the chemical — attached to insulin in the spray droplets — will help the hormone seep as far as the tiny blood vessels that lie beneath the surface of the skin, where the hormone will then get absorbed into the bloodstream.   InsuLife, the Norwegian company developing the body spray, is setting up a trial involving 12 patients with type 1 diabetes to see how different doses of the spray compare with injected insulin in controlling blood-sugar levels. It is used just before a meal, like injected insulin.   The clinical trial was set up after a study involving five people found the spray reduced blood sugar levels by about 20 per cent after a meal. https://www.dailymail.co.uk/health/article-12965203/insulin-spray-arm-diabetes-jab-Hope-sight-millions.html XX The FDA clears the Qvin's Q-Pad™ A1c Test System which uses menstrual blood to get an A1C result. The kit is intended for the collection of menstrual blood samples by individuals 18 years of age and older using the Q-Pad, a pad with an embedded blood collection strip (Q-Strip). Each kit includes 2 Q-Pads, a return sample container, and a stamped mailing pouch. The FDA clearance was based on data from a clinical validation study that included 198 participants. Samples were collected using the Q-Pad Kit and were returned to the laboratory by mail. To provide the reference sample, a venous blood draw was performed on participants by a phlebotomist. An analysis of both samples demonstrated that the clinical performance of the Q-Pad test system in measuring HBA1c was equivalent to the traditional method of blood testing. https://www.empr.com/home/news/fda-approved-q-pad-test-system-uses-menstrual-blood-to-measure-hba1c/ XX Learning more about Dexcom's upcoming CGM designed for people with type 2 who don't use insulin. It's to be called Stelo and they've submitted to the FDA with an eye on a late summer launch. I was at the announced last June – this is a system that will have very few alerts and alarms.. Stelo looks a lot like the G7 but will have different software and will last for about 15 days per sensor. https://www.theverge.com/2024/1/11/24034098/dexcom-stelo-cgm-diabetes-health-tech-ces-2024 XX Tandem Diabetes Care's t:slim X2 Insulin Pump Automated Insulin Delivery System is now the first to incorporate the Abbott FreeStyle Libre 2 Plus Sensor for users in the United States. The FreeStyle Libre 2 Plus sensor is a modified version of the FreeStyle Libre 2 sensor cleared in 2023 by the US Food & Drug Administration for use with automated insulin delivery (AID) systems. The move follows Tandem's December announcement of integration with the recently available 10-day Dexcom G7 sensor. https://www.medscape.com/viewarticle/tandem-insulin-pump-system-integrates-libre-sensor-2024a10000iq?form=fpf XX If you use Omnipod 5 with an Android, there's a software update you need to do. The FDA has issued a Class one correction recall. due to a software error that occurs when the user enters a bolus amount less than 1 unit without putting a leading zero before the decimal point. This recall is not a product removal and users should have already received an alert that won't let them use the app until they do the software update. https://www.fda.gov/medical-devices/medical-device-recalls/insulet-corporation-recalls-omnipod-5-android-app-due-software-error#:~:text=Reason%20for%20Recall,zero%20before%20the%20decimal%20point. XX   Embecta continues to move ahead with its insulin patch pump.. submitting a 510(k) premarket filing to the FDA for its proprietary insulin patch pump. This is a disposable pump for people with type 2 diabetes. It also has a closed-loop version under development to follow. That version features an embedded algorithm that requires Embecta to run a clinical study. Henry Anhalt, chief medical officer, says nine out of 10 people with diabetes live with type 2 diabetes. However, Anhalt says the majority of automated insulin delivery systems cater to those with type 1 diabetes. Embecta aims to offer more options and tools to the broader diabetes care community, he says.   https://www.drugdeliverybusiness.com/embecta-submits-insulin-patch-pump-fda/ XX Update on insulin prices.. as a few prices changes went into affect at the beginning of the year. So, what took effect this month was that Sanofi followed suit with Eli Lilly and Novo Nordisk to implement this cap on insulin co-pays at $35 that took effect January 1. And that comes after the provisions of the Inflation Reduction Act capped insulin for people on Medicare at $35. The Medicare cap is automatic and part of policy. For everyone with commercial insurance, the cap is voluntary from the companies. For those without government or private insurance, the picture is more complicated. If your insulin is still more than $35 per month, ask your pharmacist for coupons or check out getinsulin dot org. https://www.pbs.org/newshour/show/new-law-caps-insulin-prices-for-some-with-diabetes-but-cost-remains-high-for-millions   XX       Commercial XX XX Young adults who reported higher stress during their teenage years to adulthood were more likely to have high blood pressure, obesity and other cardiometabolic risk factors than their peers who reported less stress, according to new research published today in the Journal of the American Heart Association, an open access, peer-reviewed journal of the American Heart Association. Cardiometabolic risk factors often occur together and are a significant cause of cardiovascular disease. These include obesity, Type 2 diabetes or prediabetes, high cholesterol and high blood pressure, researchers noted. In 2020, cardiometabolic diseases, including cardiovascular diseases and Type 2 diabetes, were the most prevalent chronic health conditions and collectively accounted for nearly a quarter of all deaths in the U.S., according to the American Heart Association statistics. In 2023, the American Heart Association noted the strong connections among cardiovascular disease, kidney disease, Type 2 diabetes and obesity, and suggested redefining cardiovascular risk, prevention and management.   https://finance.yahoo.com/news/childhood-stress-linked-higher-risk-100000670.html XX Shout out to NBC News for a great story they did recently on LADA – featuring two women who have both been on this podcast. Dr. Phyllisa DeRoze and Mila Clark were both first misdiagnosed with type 2 before they got a correct diagnosis of LADA. I'll link up the NBC story along with our chats with both women.. thanks to Mila for giving me a mention as one of the voices in the diabetes community who made her think was she had might not be type 2.. but could be LADA. https://www.nbcnews.com/health/diabetes/diagnosed-type-2-diabetes-may-different-form-disease-rcna132571     XX Join us again soon!

Welcome to the MassDevice Fast Five medtech news podcast, the show that keeps you up-to-date on the latest breakthroughs in medical technology. Here's what you need to know for today, January 8, 2024. Check out the show notes for links to the stories we discussed today at MassDevice.com/podcast. The FDA cleared Butterfly Network's next-generation handheld ultrasound technology. Fast Five hosts Sean Whooley and Danielle Kirsh take a look at the technology and the recent steps taken by Butterfly Network to continue growing its business. Medtronic won CE mark approval for the MiniMed 780G automated insulin pump with the Simplera Sync disposable, all-in-one CGM. Find out more details on the company's newest CGM technology and how it can benefit people with diabetes in Europe with this approval. Abbott has integrated its FreeStyle Libre 2 Plus into Tandem Diabetes Care's automated insulin pump technology. The hosts break down the latest CGM-insulin pump integration news and look at how this can benefit people with diabetes. LivaNova plans to wind down its advanced circulatory support business unit. The company is the latest to take action to narrow its focus by shifting its organizational structure. Learn more about what this decision entails. Boston Scientific plans to acquire Axonics for $3.7B. One of the busiest companies on the M&A front in medtech has made yet another move, with this one providing a major boost to its Urology portfolio. The Fast Five hosts explain the details of the acquisition and how it folds into Boston Scientific's broader strategy.

In today's episode, I talk about a device that is reshaping the landscape of personal health — Continuous Glucose Meters (CGMs). Join me as I go over the importance of CGMs and their impact on the lives of our clients. From monitoring glucose levels to unveiling crucial insights into metabolic health, I explore how CGMs are not just devices but catalysts for positive change. So let's dive in and discover the transformative power of CGMs together.IN THIS EPISODE:Importance of Continuous Glucose Meters (CGMs)Continuous Glucose Meters (CGMs) play a crucial role as valuable tools in monitoring glucose levels continuously, especially considering that 93% of the population exhibits signs of metabolic illness, indicating issues with glucose and insulin regulation. The significance lies in the ability to monitor glucose to address potential health challenges, ranging from common issues like excess belly fat and fatigue to more severe conditions such as kidney problems and cardiovascular issues. Therefore, the continuous tracking provided by CGMs is essential for understanding and managing the metabolic health of our clients.How and Where to Get CGMsCGMs, exemplified by brands like Dexcom and Abbott Freestyle Libre, are devices affixed to the arm or belly to monitor glucose levels continuously. Multiple companies manufacture CGMs, and practitioners can recommend these devices for their clients. There are various CGM models, such as Dexcom G6, Freestyle Libre 2, and the more recent Dexcom G7 available. While encountering resistance in prescribing through conventional means, there are alternative avenues for you and your clients to acquire CGMs, including online pharmacies and third-party companies, expanding accessibility to these valuable monitoring tools.CGM Issues and HesitationsAlthough CGMs are revolutionary tools in managing and understanding metabolic health, like any technology, they come with certain issues and concerns. One primary concern revolves around the perceived pain associated with CGM insertion. While the devices are designed to be relatively painless, users may still experience initial discomfort or apprehension. Financial considerations also play a role, with some individuals facing challenges in covering the costs of CGMs. However, solutions such as exploring coupons or prescription assistance programs can help alleviate this concern. Integrating CGMs into daily life activities, like showering or swimming, raises questions about the devices' durability and practicality. While addressing these concerns, the podcast emphasizes the importance of educating users on calibrating and spot-checking for accuracy, offering insights into optimizing CGM use. Additionally, privacy and data security concerns arise, prompting a need for individuals to understand how their data is handled and stored. Important ReInvent Healthcare Links Access Additional Resources for Practitioners ready to improve clinical outcomes through our Nutritional Endocrinology Practitioner Training. Visit the ReInvent Healthcare site to check out other podcast episodes and resources to support you in empowering your clients health recovery journeysCheck out my Insulin Resistance Course here. Learn more about Theia Health here.

It's In the News, a look at the top stories and headlines from the diabetes community happening now. Top stories this week: an existing drug for arthritis is being studied for treatment of T1D, poison control centers report a big increase in calls about misdosing of Ozmepic and semaglutides, Tandem releases it's Tandem Source software, we've got an update on a possible non invasive glucose monitoring system, ADA releases it's standards of care and more! Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Take Control with Afrezza  Omnipod - Simplify Life Learn about Dexcom  Edgepark Medical Supplies Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens  Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX In the news is brought to you by Edgepark simplify your diabetes journey with Edgepark XX Our top story this week… XX A world-first clinical trial has found a common drug used to treat rheumatoid arthritis can suppress the progression of type 1 diabetes in recently diagnosed patients. Australian reserachers say they've discovered that baricitinib *bare-uh-sit-en-ub* can preserve the body's own insulin production. The scientists recruited 91 people, aged between 10 and 30 years old, to take part in the double-blind randomised trial. All patients had been diagnosed with type 1 diabetes within the last 100 days and continued with their prescribed insulin therapy throughout the study. The results showed those in the baricitinib group were able safely and effectively to preserve their body's own insulin production and suppress the progression of type 1 diabetes. "Our trial showed that, if started early enough after diagnosis, and while the participants remained on the medication, their production of insulin was maintained. "People with type 1 diabetes in the trial who were given the drug required significantly less insulin for treatment." Dr Faye Riley, research communications manager at Diabetes UK, said of the latest trial: "These findings show by tackling the root of type 1 diabetes - an immune system attack - an existing drug can help to shield the pancreas, in people recently diagnosed with type 1, so they can continue making more insulin for longer. "This can give people with type 1 diabetes much steadier blood sugar levels and help to protect against serious diabetes complications down the line. "Immunotherapies are edging us towards a new era in type 1 diabetes treatment, and could help us overcome a major hurdle en route to finding a cure for the condition. "This trial takes us another step closer." The study was funded by JDRF, a non-profit organization which focuses on type 1 diabetes research. The research has been published in the New England Journal of Medicine. https://news.sky.com/story/world-first-trial-finds-arthritis-drug-may-help-treat-type-1-diabetes-13024706 XX Earlier this month, Dexcom's G7 became compatible with two pump systems: Beta Bionic's ilet pump and Tandem Diabetes tslim X2. Current customers should have received instructions on how to download the updated software – new pumps will be shipped with G7 software already loaded. Tandem has also announced their new Tandem Source platform – full launch in the US with international rollout slated for next year. Anyone in the U.S. who uses a Tandem pump—as well as their respective healthcare providers—will now have access to the Source platform. On the patient side, insulin dosage data will automatically transfer from the pump to the platform, by way of the t:connect mobile app, where it'll be compiled into three reports for your doctor. Patients will also be able to use the platform to access new software updates for their pumps and to reorder supplies as needed. Long term, the company hopes to use the data from users – which would be blinded- to update automated insulin dosing algorithms. https://www.fiercebiotech.com/medtech/tandem-begins-full-us-rollout-source-diabetes-management-platform XX New look at benefits from a plant based diet – this research says it can reduce the risk of type 2 diabetes by 24%. It's not just about weight loss. They reviewed data on more than 113,000 participants in a large-scale British observational study, gathered over 12 years. They found that normal values for cholesterol, blood sugar, inflammation, and insulin are associated with a low risk of diabetes. They also found that good liver and kidney function is important in diabetes prevention. A plant based diet helped with all of those factors. The researchers do point out that there is such a thing as an unhealthy plant-based diet. Those that are still high in sweets, refined grains and sugary drinks are associated with an increased risk of type 2 diabetes, researchers found. https://www.usnews.com/news/health-news/articles/2023-12-13/plant-based-diets-cut-diabetes-risk-by-24 XX Reports of more patients with type 2 diabetes having trouble getting coverage for medication like Ozempic and Mounjaro – because health insurance companies are putting new restrictions in place. Most U.S. health plans cover GLP-1s for type 2 diabetes but many providers will prescribe it off label for weight loss. There is another medication – Wegovy – approved for weight loss, it's the same drug as Ozempic just packaged in a difference dose and name. The average number of weekly Ozempic prescriptions rose 33% between the first and third quarters of this year, but has since dropped more than 6% to about 431,000, according to Iqvia Institute for Data Science. Doctors and patients are bracing for changes in January, when individual health plans often set new coverage terms. "It may be that January 1, all of a sudden something that was covered is no longer," said Dr. Robert Gabbay, chief science officer at the American Diabetes Association. https://www.reuters.com/business/healthcare-pharmaceuticals/us-diabetes-patients-face-delays-insurers-tighten-ozempic-coverage-2023-12-12/ XX Poison control centers across the US say they are seeing a steep increase in calls related to semaglutide, with some people reporting symptoms related to accidental overdoses. From January through November, the America's Poison Centers reports nearly 3,000 calls involving semaglutide, an increase of more than 15-fold since 2019. In 94% of calls, this medication was the only substance reported. The compounded versions of semaglutide are often different from the patented drug. Many contain semaglutide salts called semaglutide sodium and semaglutide acetate. The FDA says the salt forms of the drug have not been tested and approved to be safe and effective the way the patented form of the medication has, and thus they don't qualify for the compounding exemption in the law for drugs in shortage. In other cases, the compounded versions are sold in unapproved dosages. But these compounded versions are popular because they may cost less out-of-pocket, especially if the treatment isn't covered by insurance. The name-brand drugs are sold in pre-filled pens, which come with some safeguards. Patients dial to the correct dose and click to inject, so it's harder to make mistakes. Compounded versions, however, typically come in multidose glass vials, and patients draw their own doses into syringes. It's easy to get confused. https://www.cnn.com/2023/12/13/health/semaglutide-overdoses-wellness/index.html XX XX Type 2 diabetes patients who received endocrinology care through telehealth alone had poor glycemic outcomes compared with those who received in-person or hybrid care, which contrasts with prior research findings, according to a new study. Previous research has shown that telehealth is effective in improving glycemic control, but there has not been enough data on utilization and outcomes linked to routine telehealth care for type 2 diabetes since 2020, especially in the endocrinology setting, the researchers wrote. One reason may be that the strategies to support glycemic improvement deployed during in-person appointments, like self-management education and sharing home blood glucose data, have not been consistently translated to telehealth. “Implementation of approaches to overcome these differences, such as team-based virtual care and technological tools to automate blood glucose data sharing, are needed to ensure all patients receive high-quality diabetes care regardless of care modality,” they wrote. These study findings contrast with previous research, including a study published in early 2022 that revealed that telehealth maintained quality of care and led to better health outcomes for patients with type 2 diabetes during the COVID-19 pandemic. The study included 16,588 with type 2 diabetes who received care before or during the pandemic, with 7,581 having a telehealth visit with either a primary care physician or an endocrinologist. https://mhealthintelligence.com/news/telehealth-only-care-fails-to-improve-type-2-diabetes-outcomes XX Medtronic's deal to buy a South Korea based insulin patch pump maker is off. Back in May Medtrnoic announced a 738-million dollar deal to buy EOFlow, which makes EOPatch, a tubeless, wearable and fully disposable insulin delivery device. EOFlow already launched its EOPatch insulin delivery system in Korea and Europe. The company submitted the insulin delivery device for U.S. FDA clearance in January. https://www.massdevice.com/medtronic-nixes-738m-deal-for-insulin-patch-pump-maker-eoflow/ XX Commercial XX Update on non invasive continuous glucose monitoring. The most recent validation of the technology's accuracy has been released as a preprint. In an experiment, researchers fed thousands of radio frequency glucose readings into a machine learning model to translate them into blood sugar values and compared the results against those from a Dexcom G6. CGM accuracy is judged by mean absolute relative difference, or MARD. The statistic is reported as a percentage: a MARD of 10 percent, for example, means that the CGM is on average within 10 percent of the reference value. The Bio-RFID system scored a MARD of 11.27 percent. In truth, this result is difficult to interpret. Though Bio-RFID's MARD is not yet in the same neighborhood as its competitors' (the Freestyle Libre 3 and the Dexcom G7 report MARDs of 7.9 percent and 8.7 percent, respectively), the experiment wasn't a true test of the device's capabilities, because it didn't use a lab-drawn glucose measurement as its reference value. The volunteers also did not have diabetes, which meant that their blood sugar levels were likely more stable than those of most future customers. The FDA has specific accuracy standards that it expects CGM manufacturers to meet for devices intended for “nonadjunctive” use and for use in a closed-loop insulin pump system. Know Labs's product will need to meet these objective standards to be validated as a truly reliable CGM. The Path to Approval “Our expectation is that we'll be in front of the FDA as we move into the second half of 2024,” says Erickson. Much larger trials will be needed to show that the device works and meets FDA standards. Erickson says, “We expect to have an FDA-cleared device in 2025.” Though the business is still finalizing the form of the next generation, it expects that it can navigate the FDA approval process quickly. The FDA has already confirmed that RFID is quite safe and there should be little worry about side effects (though there could be a hazard of interference for patients already using electronic medical devices such as pacemakers). https://www.diabetesdaily.com/blog/this-company-is-racing-to-create-the-worlds-first-non-invasive-cgm-718069/ XX Today, the American Diabetes Association® (ADA) released the Standards of Care in Diabetes—2024 (Standards of Care), a set of comprehensive and evidence-based guidelines for managing type 1, type 2, gestational diabetes, and prediabetes based on the latest scientific research and clinical trials. It includes strategies for diagnosing and treating diabetes in both youth and adults, methods to prevent or delay type 2 diabetes and its associated comorbidities like cardiovascular disease (CVD) and obesity, and therapeutic approaches aimed at minimizing complications and enhancing health outcomes. "The latest ADA guidelines present pivotal updates for health care professionals, ensuring comprehensive, evidence-based care for diabetes management. These changes reflect our ongoing commitment to optimizing patient outcomes through informed, adaptable, and patient-centered health care practices,” said Robert Gabbay, MD, PhD, the ADA's chief scientific and medical officer. “The ADA's Standards of Care ensures health care professionals, especially our primary care workforce, provide the best possible care to those living with diabetes.” Notable updates to the Standards of Care in Diabetes─2024 include: New updates in managing obesity in people with diabetes, including approaches to reduce therapeutic inertia, support more personalization, and incorporate additional obesity measurements beyond body mass index (i.e., waist circumference, waist-to-hip ratio, and/or waist-to-height ratio). New screening recommendations for heart failure in people with diabetes. Updated recommendations for peripheral arterial disease (PAD) screening in people with diabetes. Guidance on screening and the use of teplizumab, approved to delay the onset of type 1 diabetes. More guidance on the use of new obesity medications, glucagon-like peptide 1 (GLP-1) agonists or dual glucose-dependent insulinotropic polypeptide (GIP) receptor agonists, to reach sustained weight management goals. Updates in guidance on the diagnosis and classification of diabetes. A focus on hypoglycemia prevention and management. Emphasis on screening people with diabetes for nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis at primary care and diabetes clinics. New emphasis on the evaluation and treatment of bone health and added attention to diabetes-specific risk factors for fracture. A focus on screening and management of people with diabetes and disability. Emphasis on enabling health care providers to master diabetes technology, using artificial intelligence for retinal screenings with necessary referrals, and embracing telehealth and digital tools for diabetes self-management education. New information on the possible association between COVID-19 infections and new onset of type 1 diabetes. "As the ADA's chair of professional practice committee, I'm excited to share our latest updates to advance diabetes care through new scientific insights and technological innovation, all aimed at enhancing experience for people with diabetes and health care professionals in managing this complex condition," said Nuha A. El Sayed, MD, MM Sc, the ADA's senior vice president of health care improvement. Other noteworthy changes to the 2024 Standards of Care include: Updated immunization guidance to include newly approved RSV vaccines in adults over 60 years of age with diabetes. New emphasis on cultural sensitivity in diabetes self-management education, with considerations for changing reimbursement policies. More detail and emphasis on psychosocial screening protocols to better identify diabetes distress. The importance of diabetes technology, with an emphasis on continuous glucose monitors (CGMs) and automated insulin delivery (AID) systems. Continued emphasis on inclusion and person-centered care. “At the ADA, we are focused on improving the quality of care for anyone who lives with diabetes, prediabetes, or who is at risk of developing diabetes. The Standards of Care is critical to ensuring the improved treatment of diabetes, a chronic disease that requires continuous care through a well-informed and coordinated health care team. These standards equip health care professionals with the gold standard in diabetes care, ensuring the highest level of service and knowledge in the field,” said Chuck Henderson, the ADA's chief executive officer. The ADA annually updates its Standards of Care through the efforts of its Professional Practice Committee (PPC). Comprising 21 global experts from diverse professional backgrounds, the PPC includes physicians, nurse practitioners, certified diabetes care and education specialists, registered dietitians, pharmacists, and methodologists. Its members hold expertise in areas like adult and pediatric endocrinology, epidemiology, public health, cardiovascular risk management, kidney disease, microvascular complications, preconception and pregnancy care, weight management, diabetes prevention, behavioral and mental health, inpatient care, and technology in diabetes management. Additionally, the committee collaborates with 19 specialized content experts. The 2024 Standards of Care has garnered endorsements from the American College of Cardiology (Section 10), the American Society of Bone and Mineral Research (Bone section in Section 4), and the Obesity Society (Section 8). Today, the Standards of Care in Diabetes—2024 is available online and is published as a supplement to the January 2024 issue of Diabetes Care®. A shortened version of the guidelines, known as the Abridged Standards of Care, will be made available for primary care providers in the journal Clinical Diabetes®, along with a convenient Standards of Care app as well as a Standards of Care pocket chart. The online version will be annotated in real-time with necessary updates if new evidence or regulatory changes merit immediate incorporation through the “living” Standards of Care process. Other Standards of Care resources, including a webcast with continuing education (CE) credit and a full slide deck, can be found on the ADA's professional website, DiabetesPro®. https://diabetes.org/newsroom/press-releases/american-diabetes-association-releases-standards-care-diabetes-2024 XX Join us again soon!  

Meet Simone Carniglia, Six-Star finisher, and Guinness World Record holder as the fastest runner with Type One diabetes—with an amazing average time of 2:42:30 per race! Simone started his running journey to lose weight and was inspired by Stefano Baldini, the great Italian marathoner who won the gold medal at the 2004 Athens Olympics. Running these incredibly fast times is impressive, but for a diabetic, it is significantly more challenging. A diabetic marathoner has to continuously control blood sugar levels in order to be safe, not faint, and perform at their best. They're more subject to cramping and dehydration during physical activity, especially when glucose levels aren't managed properly. Simone has only been running for five years and is just getting started. He hopes his journey will inspire many other diabetic athletes to not give up on their dreams and never give up. Simone's story proves that with the right training, nutrition, therapy, strategy, and use of the latest technologies—such as Abbott Global and Freestyle Libre 3—diabetic runners can achieve amazing results that weren't imaginable just a few short years ago Simone is grateful for the Abbott Global profile they featured on him for World Diabetes Day and is excited to get started on a second round of World Marathon Majors. I'm rooting for Simone to keep inspiring and look forward to seeing him out there in 2024! If you enjoy the episode, it would mean the world to me if you would rate the podcast or write a review and share feedback wherever you get your podcast groove on. Connect With Simone: Instagram: https://www.instagram.com/simone.carniglia All Other Links: https://linktr.ee/6majorswitht1d Connect With Ron: Personal Instagram: https://www.instagram.com/ronrunsnyc Podcast Instagram: https://www.instagram.com/runchats_with_ronrunsnyc Facebook: https://fb.me/runchats Website: https://ronrunsnyc.com ---- Produced by: David Margittai | In Post Media Website: https://www.inpostmedia.com Email: david@inpostmedia.com Social: https://www.instagram.com/_margittai © 2023 Ron Romano

It's In the News, a look at the top stories and headlines from the diabetes community happening now. Top stories this week: Novo Nordisk will discontinue Levemir by the end of 2024, Tandem begins limited launch of software updates that will include Dexcom's G7, Beta Bionics iLet pump will be covered until some pharmacy plans, and lots more! Links and transcript below Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Take Control with Afrezza  Omnipod - Simplify Life Learn about Dexcom  Edgepark Medical Supplies Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens  Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com   Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX In the news is brought to you by Edgepark simplify your diabetes journey with Edgepark XX This week was World Diabetes Day so there is a LOT going on.. Our top story is XX Novo Nordisk said on Wednesday it would discontinue its long-acting insulin Levemir in the United States, citing manufacturing constraints, reduced patient access and available alternatives. The Danish drugmaker said supply disruptions would start in mid-January, followed by discontinuation of the Levemir injection pen in April and of Levemir vials by the end of 2024. Novo has another long-acting insulin, Tresiba, on the market and says quote - "global manufacturing constraints, significant formulary losses impacting patient access effective in January 2024, and the availability of alternative options in the U.S. market" are key factors in the decision. The announcement comes eight months after Novo said it would cut U.S. list prices for several of its insulin products next year, including a 65% reduction in the list price of Levemir. Novo, which overtook LVMH (LVMH.PA) as Europe's most valuable listed company this year, posted record operating profit for the third quarter, with sales of its obesity drug Wegovy reaching $1.36 billion, up 28% from the previous quarter. https://www.reuters.com/business/healthcare-pharmaceuticals/novo-nordisk-discontinue-levemir-insulin-us-market-2023-11-08/ XX Big news from Tandem Diabetes this week – first, their Control IQ algorithm gets FDA approval for children as young as two years old. the technology's original 2019 clearance limited its use to those aged 6 and older. And.. they are officially rolling out the software update that will allow users to connect to either the Dexcom G6 or G7 CGM. If you're in the limited launch you got an email this week telling you the next steps – wider release is expected gradually in the first part of 2024. Integration with Abbot's FreeStyle Libre is expected very soon as well – which would mean Tandem's tslim x2 and Mobi pumps would be compatible with three CGMs. Full disclosure: there wasn't a media release that I received on this, but my son is in the limited launch group so we got the email.   https://www.fiercebiotech.com/medtech/tandem-diabetes-care-cruises-fda-ok-toddler-use-automated-insulin-delivery-algorithm XX Beta Bionics iLet pump and its supplies are now covered as part of some pharmacy benefits - Express Scripts added it to its national formulary list. Historically, insulin pumps fall under the durable medical equipment (DME) insurance benefit. Usually pharmacy benefits are more flexible with fewer up front costs. The system uses an adaptive, closed-loop algorithm that initializes with the user's body weight and requires no additional insulin dosing parameters. The algorithm removes the need to manually adjust insulin pump therapy settings and variables. iLet simplifies mealtime use by replacing conventional carb counting with its meal announcement feature. This enables users to estimate the amount of carbs in their meal, categorized as “small,” “medium” or “large.” Over time, the algorithm learns to respond to users' individual insulin needs. https://www.drugdeliverybusiness.com/beta-bionics-pharmacy-benefit-bionic-pancreas/ XX The UK has launched a pioneering study to explore the development of type 1 diabetes in adults which aims to screen 20,000 individuals. Research will enable earlier and safer diagnosis of type 1 diabetes through blood tests. This makes the UK the first country to implement general population screening for type 1 diabetes in both children and adults. The Type 1 Diabetes Risk in Adults (T1DRA) study, launched on World Diabetes Day, seeks to enroll 20,000 adults aged 18 to 70. Supported by The Leona M. and Harry B. Helmsley Charitable Trust and building on the Diabetes UK-funded Bart's Oxford Family study (BOX), T1DRA aims to unravel the mysteries of adult-onset type 1 diabetes. https://www.diabetes.co.uk/news/2023/nov/groundbreaking-study-to-screen-20000-adults-for-type-1-diabetes.html XX The National Institute for Health and Care Excellence (NICE), England's cost-effectiveness watchdog, has finalized a draft guidance regarding hybrid closed-loop systems, concluding that the technology should be made broadly affordable and accessible to help people with Type 1 diabetes better manage the condition. In this month's final draft guidance (PDF), NICE recommended that hybrid closed-loop technology be offered to all people with Type 1 diabetes who are having trouble controlling the condition using their existing devices.   NICE said that it has already devised a five-year rollout plan with the NHS to bring the technology to people with Type 1 diabetes. Hybrid closed-loop systems will be offered first to children, young people, existing insulin pump users and women who are pregnant or planning to become pregnant, after which they'll be issued to adults who have an average HbA1c reading of at least 7.5%. https://www.fiercebiotech.com/medtech/nice-recommends-hybrid-closed-loop-systems-type-1-diabetes-prompting-praise-medtronic XX     Commercial XX Kyle Banks was diagnosed with type 1 diabetes on November 1, 2015 while performing with the traveling production of Disney's The Lion King.  Performing nightly for sold out audiences across the country was a dream come true, but after experiencing symptoms of the onset of type 1 diabetes, the dream temporarily turned into a nightmare. The symptoms he experienced were  typical for the onset of this chronic illness. but with limited knowledge of type 1 diabetes, he had no idea what was occurring or the drastic life change that would soon follow.  In 2020, he founded Kyler Cares in partnership with Children's Hospital New Orleans and has since connected with families from across the country that are living with this disease.  Kyler Cares seeks to improve health outcomes for people of color living with diabetes and ensuring families can access the resources and technology available for better management is the route the organization is taking to achieve that goal. At Kyler Cares we're working to improve health outcomes for people of color living with diabetes by improving access to diabetes technology, creating connections to education and resources, and fostering community as an added system of support on our journeys. Kyler Bear & Friends' T1 Diaries is an eight-part animated series for kids, dedicated to storytelling about life with Type 1 Diabetes. Our series is more than just an educational tool; it's a reflection of real-life stories and an avenue to strengthen community ties. It's a vehicle for us to inspire young people to begin laying a foundation of knowledge and self-confidence with management of T1D that will resonate throughout their lives until a cure for the disease is discovered.   By supporting this series with a donation, you will be contributing to a project that not only educates and informs but also offers comfort and a sense of belonging to kids navigating life with T1D. ‘Kyler Bear's T1 Diaries' isn't just a series; it's a beacon of hope, a source of information, and a testament to the strength found in our amazing T1D community. Join us in bringing these stories to life XX Married At First Sight UK ends this week, but one bride says viewers haven't seen her whole story.   Fans will find out if Tasha Jay, 25, decides to stay with partner Paul Liba on the Channel 4 show.   But Tasha, who has type 1 diabetes, has spoken out about how footage about her condition didn't make the final cut.   While she's "really sad" that it was left out, Tasha's pleased that people are now realising why she behaved in a certain way on the show at times.     Married at First Sight - or MAFS - is a social experiment where experts match complete strangers who try to live as a couple.   Tasha says her wedding day with Paul on the show was a "really beautiful moment" that included her telling Paul about her diabetes and his reaction.   "I got filmed taking my insulin and checking my blood sugar," she tells BBC Newsbeat.. Tasha was diagnosed at aged two and half and says people have asked why that part of her was hidden in the show.   "And I'm like I didn't hide it," she says.   "For whatever reason they haven't shown it, which really upsets me because diabetes is a part of my story."   Tasha believes that, if people had known about her diabetes, it would have changed their perception of certain moments in the show. https://www.bbc.com/news/newsbeat-67368445

Wellness + Wisdom | Episode 581 Is biomarker blood testing the future of real healthcare? Michael Dubrovsky, co-founder of SiPhox, joins Josh Trent on the Wellness + Wisdom podcast, episode 581, to reveal how at-home biomarker blood testing is revolutionizing people's health journey, why the healthcare system should adopt a preventative approach, and how you can combine blood testing with wearables for best results. "We went after at-home blood testing to put a device in every home in America and make it possible for people to have easy access to this rather than making blood testing reactive, where "I have terrible symptoms, now I'm going to get a bunch of blood work." SiPhox is making it proactive so that people are getting much more blood tests and that's the cornerstone of the whole medical journey." - Michael Dubrovsky 10% Off SiPhox The SiPhox Health at-home test kit measures 17 blood biomarkers of inflammation, hormonal health, metabolic fitness, and cardiovascular health. 10% off with code "JOSH" Track how your body responds to your lifestyle, diet, and supplements to reach your health goals faster. Regular testing lets you optimize your diet and lifestyle choices so you can live your healthiest, happiest life. You can also correlate data with your wearable: Accu-Chek, Oura, Garmin, Whoop, Apple Watch, Freestyle Libre, Dexcom, and Fitbit. In This Episode, Michael Dubrovsky Uncovers: [01:30] SiPhox At-Home Biomarker Blood Testing Michael Dubrovsky SiPhox Health - Use code "JOSH" for 10% off Mike's journey to biotech. How the SiPhox Health technology works. Diedrik Vermeulen Why the current blood testing system is not innovative. [08:40] Is Preventative Medicine The Solution to The Broken Healthcare System? How the chip reads the blood sample. Explaining how you can create a blood sample at home. Josh's experience with SiPhox. How people can take better care of their health with preventative medicine. Why life expectancy is not increasing in the U.S. but it is increasing in other parts of the world. How data helps healthcare evolve. [18:45] The Modern Health + Healthcare Problems 1/3 of Americans are going to suffer from diabetes in the future. Why many doctors don't want to do a full comprehensive blood panel. The healthcare system doesn't support the preventative approach. Daniel Kahneman How Josh heals his health issues with natural medicine. [22:50] Is Technology Helping Us or Hurting Us? Peter Diamandis Why it takes over 17 years for a breakthrough to make it to the medical practice. Is the answer to health going back to nature or modern technology? SiPhox's mission and vision. Why companies that raise a lot of money usually don't do the best. [32:25] Genetic Testing VS Blood Testing How Michael and the SiPhox team developed the device. Why blood tests are more valuable than genetic tests. The reason why food sensitivities at-home tests are the most effective. 60% of Americans have a chronic disease. How C-reactive proteins (CRP) influence lifespan. [41:05] Chronic Disease Testing Why SiPhox decided to test more chronic diseases apart from high CRP. Understanding different indicators of disease. Why hormone testing is more accurate when you can control when you take the test. What gets measured, gets managed. [47:50] Plastics Leach Harmful Chemicals Why plastic causes people to have low testosterone. How BPA was replaced with another type of plastic that is also unsafe. 293 Dr. Jade Teta: How To Be A Next Level Human “Chemical Castration”: White Genocide and Male Extinction in Rhetoric of Endocrine Disruption How the market can create a change if they reject the items that are hurting us. Why high thyroid-stimulating hormone (TSH) negatively affects thyroid function. [57:45] Striving to Achieve Health Abundance Why Michael takes blood tests often. How blood testing lets you know what you should work on. Why abundance of health is most valuable to Josh. The reason why Michael wants to improve his metabolic health. What the genome sequence can show you. [01:08:05] Silicon Photonic Biosensors What went wrong with Theranos. Why blood testing companies are more transparent about how everything works since Theranos. LL Cool J How SiPhox is aiming to deliver the same accuracy as central labs. Why pharmaceutical drugs are more profitable than at-home blood tests. [01:22:55] Address All Aspects of Your Health 048 Nir Eyal: Breaking Bad Habits, Technology Addiction, & Emotional Triggers How using wearables can help people understand their health patterns. Oura Ring How SiPhox connects to Oura ring and 200 other wearables. [01:28:25] Optimize Your Health with Blood Tests Gattaca Michael's opinion on American food. Why every person should get tested four times a year if they're trying to optimize their health. What comes in the SiPhox at-home blood test kit. How long-term thinking can help you get better results. Why SiPhox can be a support to wellness practitioners. Leave Wellness + Wisdom a Review on Apple Podcasts Power Quotes From The Show Biomarker Blood Testing "The way we view biomarker blood testing is like this panel is the base panel, you should be getting it frequently. We have add ons that allow you to look deeper at certain things. And that's how most engineers will debug a system, right? You do something broad and simple and you kind of see what's going on here and these are all biomarkers that are really well studied, very commonly if something's out of the range, and then we go deeper down a particular rabbit hole." - Michael Dubrovsky Life Expectancy in the U.S. "Life expectancy is not increasing while cost is increasing in the standard medical system and that is not true in Europe. If you look at all the European countries, everybody's life expectancy is increasing and the cost is not increasing that much. America is just obviously broken. We don't have a very strong opinion of how to fix it beside you need more data and you need more control over the situation." - Michael Dubrovsky The Evolution of the Medical System "Medicine is getting better but it's too expensive for most people to get that kind of scrutiny. Having more data makes it easier. If you give a doctor lots of data, such as 5 years of blood tests, the chances that they're going to give you an answer quickly is very high." - Michael Dubrovsky Limited Edition: Gold Pumpkin Spice from Organifi Save 20% with code "WELLNESSFORCE" on everyone's favorite Fall treat is here! Pumpkin Spice is more than just a taste phenomenon: it's a portal directly into the nostalgia of fall. With Gold Pumpkin Spice, that taste can also help promote relaxation and restful sleep, nourish the body, and support nightly recovery from a hard day's work.  Click HERE to order your Organifi today including the Green, Red, and traditional Gold! Are You Stressed Out Lately? Take a deep breath with the M21™ wellness guide: a simple yet powerful 21 minute morning system that melts stress and gives you more energy through 6 science-backed practices and breathwork. Click HERE to download for free. Biohack Your Mind & Body with Plunge Ice Baths!Save $150 on your PLUNGE order with code "WELLNESSFORCE" As seen on Shark Tank, Plunge's revolutionary Cold Plunge uses powerful cooling, filtration, and sanitation to give you cold, clean water whenever you want it, making it far superior to an ice bath or chest freezer. *Review The Wellness + Wisdom Podcast & WIN $150 in wellness prizes! *Join The Facebook Group Links From Today's Show  Michael Dubrovsky SiPhox Health - Use code "JOSH" for 10% off Diedrik Vermeulen Daniel Kahneman Peter Diamandis 293 Dr. Jade Teta: How To Be A Next Level Human “Chemical Castration”: White Genocide and Male Extinction in Rhetoric of Endocrine Disruption LL Cool J 048 Nir Eyal: Breaking Bad Habits, Technology Addiction, & Emotional Triggers Oura Ring Gattaca Josh's Trusted Products | Up To 40% Off Shop All Wellness + Wisdom Approved Products SiPhox - Save 10% with code "JOSH" Holy Hydrogen - Save $100 with code "JOSH" SinuSonic - Use code "JOSH15" for 15% off Tru Kava - Use code "JOSH20" for 20% off MANNA Vitality - 20% off with the code "JOSH20" Mendi.io - 20% off with the code "JOSH20" BREATHE - 33% off with the code “PODCAST33” MitoZen – 10% off with the code “WELLNESSFORCE” Organifi –20% off with the code ‘WELLNESSFORCE' PLUNGE - $150 off with the code “WELLNESSFORCE" Adapt Naturals - Save 15% with code "WELLNESSFORCE" QI-Shield EMF Device- 20% off with the code "JOSH" SEED Synbiotic - 30% off with the code "JOSHTRENT" BON CHARGE - 15% off with the code "JOSH15" SpectraSculpt - 15% off with the code "JOSH15" SaunaSpace - 10% off with the code "JOSH10" Cured Nutrition CBD - 20% off with the code "WELLNESS FORCE" LiftMode - 10% off with the code "JOSH10" Paleovalley – 15% off with the link only NOOTOPIA - 10% off with the code "JOSH10" Activation Products - 20% off with the code “WELLNESSFORCE” SENSATE - $25 off with the code "JOSH25" BiOptimizers - 10% off with the code "JOSH10" ION - 15% off with the code ‘JOSH1KS' Feel Free from Botanic Tonics - $40 off with the code "WELLNESS40" Essential Oil Wizardry - 10% off with the code "WELLNESSFORCE" ALIVE WATERS - 33% off your first order with the code "JOSH33" DRY FARM WINES - Get an extra bottle of Pure Natural Wine with your order for just 1¢ Drink LMNT – Zero Sugar Hydration: Get your free LMNT Sample Pack, with any purchase Earth Runner Shoes - Save 10% with code "JOSH10" Free Resources M21 Wellness Guide - Free 3-Week Breathwork Program with Josh Trent Join Wellness + Wisdom Community About Michael Dubrovsky Michael Dubrovsky is an engineer and entrepreneur. He is also an occasional Chinese tea-table craftsman, author, and philosopher. He is currently a Fellow in the Advanced Study Program at MIT and was previously a Visiting Researcher at Technion University in the Materials department. He holds a B.S. in Chemistry from ESF/Syracuse University. Michael has never worked full-time on a personal project from home, but when he does one day, this book will be his guiding light in the maelstrom of demotivation. Together with Diedrik Vermeulen they co-founded SiPhox Health. Website Instagram Facebook Twitter YouTube Listen To The Latest Episodes... Don't Miss New Episodes: Follow Wellness + Wisdom on Spotify  

It's In the News, a look at the top stories and headlines from the diabetes community happening now. Top stories this week: a new CGM from Medtronic is approved in Europe, semaglutides for people newly diagnosed type 1 may make a huge difference, a look at Keto diet for kids, Apple teases non-invasive glucose monitoring and Dexcom U is back! Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Take Control with Afrezza  Omnipod - Simplify Life Learn about Dexcom  Edgepark Medical Supplies Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens  Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines happening now XX In the news is brought to you by Edgepark simplify your diabetes journey with Edgepark XX Our top this story this week a new CGM from Medtronic gets approval in Europe. It's called Simplera – an all in one disposable CGM– no fingersticks and no over-tape, which is new for Medtronic. Simplera is integrated with the InPen™ smart insulin pen, which provides real-time, personalized dosing guidance to help simplify diabetes management. Medtronic will begin a phased launch at the European Association for the Study of Diabetes (EASD) 59th Annual Meeting in Hamburg, Germany on Oct. 2-6, 2023. Simplera™ is indicated for ages 2+ and compatible with iOS and Android. Simplera™ is not approved by the FDA and is limited to investigational use in the U.S. Medtronic's automated insulin delivery (AID) system integrated with this next-generation sensor is currently under review for CE Mark and is not commercially available in the U.S. or in Europe. I've reached out to Medtronic – we'll learn more soon. https://news.medtronic.com/2023-09-21-Medtronic-Diabetes-announces-CE-Mark-for-new-Simplera-TM-CGM-with-disposable-all-in-one-design XX A small study and a long way to go here, but a weekly dose of semaglutide, helped seven out of 10 patients newly diagnosed with type 1 diabetes stop taking insulin after three to six months. Semaglutide is the key ingredient in Ozempic.. approved for type 2 and Wegovy, approved for weight loss. It's also thought to tamp down the inflammation that can lead to the destruction of insulin-producing cells. He noted previous research has shown that patients with newly diagnosed type 1 diabetes still have the ability to make some of their own insulin, so the team tested semaglutide in patients within three months of their diagnosis. All ten patients were taking meal time and long acting insulin. After three months, all of them came off meal time insulin, and seven stopped basal insulin. Much more study needed here.. interestingly. Ozempic's maker, Novo Nordisk noted it didn't sponsor this study and isn't pursuing trials of semaglutide for type 1 diabetes itself, https://www.cbsnews.com/philadelphia/news/semaglutide-ozempic-wagovy-type-1-diabetes-insulin-study/ XX a widely used diabetes drug that controls blood sugar can also prevent muscle atrophy and muscular fibrosis—which can help the elderly bounce back faster from injury or illness. Researchers from the University of Utah Health have found that Metformin has surprising applications on a cellular level. Their findings were published in the journal Aging Cell. “We saw two things in our study,” Drummond says. “When participants took Metformin during a bed rest, they had less muscle atrophy. During the recovery period, their muscles also had less fibrosis or excessive collagen. That build-up can make it harder for the muscle to properly function.” https://scitechdaily.com/researchers-discover-surprising-side-effect-of-common-diabetes-drug/ XX Researchers at the Massachusetts Institute of Technology (MIT) say they have created a device for people with type 1 diabetes that may help produce insulin when needed. Their findings were published on September 18 in The Proceeding of the National Academy of Science. The MIT engineers reported that the small implantable device could carry hundreds of thousands of insulin-producing islet cells. Previous devices made for the same purpose failed and stopped producing insulin because they ran out of oxygen needed to create the insulin. To combat this, the scientists created an oxygen factory on the device, allowing it to generate oxygen by splitting water vapor in the body. The researchers said the device could potentially replace insulin injections in people with type 1 diabetes. Dr. Caroline Messer, an endocrinologist at Northwell Lenox Hill Hospital in New York, not involved in the study, explained to Medical News Today: “Currently, islet cell transplant is limited to patients with a history of severe metabolic complications and consistent failure of insulin-based therapies. Long-term success rates are low, and patients require lifelong immunosuppressive therapy. Conceptually, implantable islet cells that do not require immune suppression and create their own source of oxygen is nothing short of brilliant.” MIT researchers said the device kept glucose levels stable for at least one month when implanted into mice. The device has not yet been tested in humans. Researchers hope to create a larger version of the device and test it in people with type 1 diabetes. They expect this device to be about the size of a stick of chewing gum. “We are eager to see this technology translate, but it does take time,” said Dan Anderson, PhD, the study's lead author and a professor of chemistry at MIT. “We hope to see this technology in humans within at most four years.” Although the researchers remained focused on treating diabetes, they indicate this kind of device might be able to be adapted to treat other illnesses that require repeated delivery of therapeutic proteins. “This technology allows for an improvement in the current approach to implantation of units containing cells that produce insulin in response to blood glucose levels without requiring invasive surgery,” said Dr. Eliud Sifonte, an endocrinologist at NYU Langone Medical Associates, who was not involved in the study. “Historically, this approach has been difficult to maintain due to an inability to provide a good oxygen supply to those implanted cells,” Dr. Sifonte told MNT. https://www.medicalnewstoday.com/articles/how-a-new-device-may-help-with-insulin-production-for-type-1-diabetes XX Weight Watchers and Abbott announce their new app for people with diabetes. This is a WW app that integrates the use of a Freestyle Libre. The app helps people with diabetes understand how food and activity impact their glucose levels. WeightWatchers had a team of nutrition and behavioral science experts designed its tailored plan. It aims to help people with type 2 diabetes form helpful habits and meet their health goals. The plan has demonstrated success in helping people with diabetes lose weight and lower their HbA1c, the company said. https://www.massdevice.com/abbott-weightwatchers-unveil-connected-diabetes-app/ XX Italy celiac XX Keto and other low carbohydrate diets have gained popularity for type 2 diabetes in adults, but there are safety concerns for young people, the American Academy of Pediatrics (AAP) cautioned. Restricting carbohydrates in young people at risk for or with diabetes raises concerns for growth deceleration, nutritional deficiencies, poor bone health, nutritional ketosis, and disordered eating behaviors, Tamara Hannon, MD, of Indiana University School of Medicine in Indianapolis, and colleagues on the AAP Committee on Nutrition wrote in a clinical report to guide care. Based on demonstrated risks, low- and very low-carbohydrate diets were not recommended for children and adolescents with type 1 diabetes, "except under close diabetes care team supervision utilizing safety guidelines," the group wrote in Pediatricsopens in a new tab or window. Low-carb (

Welcome back to this week's #FridayReview where we'll be covering the very best of the week and reviewing these exciting topics:   Integrative Health Practitioner Updates New EquiLife Liquid Melatonin Weekly Podcast Recap FreeStyle Libre 3 CGM (product review) VO2 Max & Bike Test   For all the details tune into today's #CabralConcept 2737– Enjoy the show and let me know what you thought!   - - - For Everything Mentioned In Today's Show: StephenCabral.com/2737 - - - Get a FREE Copy of Dr. Cabral's Book: The Rain Barrel Effect - - - Join the Community & Get Your Questions Answered: CabralSupportGroup.com - - - Dr. Cabral's Most Popular At-Home Lab Tests: > Complete Minerals & Metals Test (Test for mineral imbalances & heavy metal toxicity) - - - > Complete Candida, Metabolic & Vitamins Test (Test for 75 biomarkers including yeast & bacterial gut overgrowth, as well as vitamin levels) - - - > Complete Stress, Mood & Metabolism Test (Discover your complete thyroid, adrenal, hormone, vitamin D & insulin levels) - - - > Complete Food Sensitivity Test (Find out your hidden food sensitivities) - - - > Complete Omega-3 & Inflammation Test (Discover your levels of inflammation related to your omega-6 to omega-3 levels) - - - Get Your Question Answered On An Upcoming HouseCall: StephenCabral.com/askcabral - - - Would You Take 30 Seconds To Rate & Review The Cabral Concept? The best way to help me spread our mission of true natural health is to pass on the good word, and I read and appreciate every review!  

In this first ever CE episode, we discuss the A-Zs of continuous glucose monitors (CGMs). In specific, our learning objective for the CE are: Describe commonly available types of continuous glucose monitors (CGMs) in the US market and the features and capabilities of these devices. Summarize the evidence and guideline recommendations for use of CGMs in the management of diabetes. Identify the role of the pharmacist in the selection of CGMs and provision of education to patients and providers. Interpret the ambulatory glucose profile (CGM data output) and recommend changes in antihyperglycemic regimen for a patient. ACPE-Accredited Pharmacist CE (1.0 hrs) To obtain CE credit for a $5 fee, visit the following link: https://rfums.wufoo.com/forms/z1qzh5vf0ggr832/. Once payment is successful, you will be redirected to our CE partner (CE Impact) to complete an evaluation and to earn 1.0 hour of CE credit. CE is available for 12 months after episode publication. Key Concepts There are two main types of stand-alone personal CGMs available in the US market – real-time (rtCGM) and intermittently scanning (isCGM). [1] These CGMs vary in their features such as sensor wear time, sensor warm up time, sensor application site, reader availability, approved age for use, fingerstick calibration, non-adjunctive FDA labeling, interconnectability with other technology such as insulin pumps, and drug interactions – these variabilities can be used in decision-making when selecting an appropriate CGM for a patient. [2-7] Based on the evidence for use, both types of CGMs (real-time and intermittently scanning) are recommended in patients with Type 1 and Type 2 diabetes who are on multiple-daily insulin or continuous insulin infusion (pump), patients with Type 2 diabetes on basal insulin therapy, and as adjunct use in patients with diabetes who are pregnant. The strength of recommendations in general is stronger for real-time CGMs than for intermittently scanning CGMs. [1,11] These recommendations are supported by the evidence that CGMs can help improve glucose control, reduce risk of hypoglycemia, diabetes-related hospitalizations, and patient/caregiver satisfaction. Pharmacists play an integral role in education, on-going support, data interpretation, and resulting disease management in patients who qualify for CGM use and providers who care for patients with diabetes. [14] The ambulatory glucose profile is a standardized data output that informs understanding of glucose trends. [15] The recommended goal for most patients is to maintain a glucose range between 70-180 mg/dL with at least 70% of time spent in this range with variability coefficient of no more than 36%. [1,11,15] Supplemental Content Comparison of rtCGM and isCGM devices "Mary's" Example AGP Report (adapted from Battelino et al.) References ElSayed NA, Aleppo G, Aroda VR, et al. American Diabetes Association. Chapter 7. Diabetes technology: Standards of medical care in diabetes - 2023. Diabetes Care. 2023;46(suppl 1):S111-S127. Dexcom G6 User Guide. Dexcom, Inc. 2020. Accessed February 20, 2023. https://s3-us-west-2.amazonaws.com/dexcompdf/G6-CGM-Users-Guide.pdf. Dexcom G7 User Guide. Dexcom, Inc. 2022. Accessed February 20, 2023. https://dexcompdf.s3.us-west-2.amazonaws.com/en-us/G7-CGM-Users-Guide.pdf#page=12 Guardian Connect System User Guide. Medtronic MiniMed. 2020. Accessed February 20, 2023. https://www.medtronicdiabetes.com/sites/default/files/library/download-library/user-guides/Guardian-Connect-System-User-Guide.pdf. Eversense E3 User Guide. Sensionics, Inc. 2022. Accessed February 20, 2023. https://www.eversensediabetes.com/wp-content/uploads/LBL-4002-01-001-Rev-F_Eversense-E3-User-Guide_mgdL_R1_web.pdf FreeStyle Libre 3 User's Manual. Abbott Diabetes Care Inc. 2022. Accessed February 20, 2023. https://freestyleserver.com/Payloads/IFU/2022/q2/ART44140-002_rev-A.pdf FreeStyle Libre 2 User's Manual. Abbott Diabetes Care Inc. 2020. Accessed February 20, 2023. https://freestyleserver.com/Payloads/IFU/2020/q2/ART40703-001_rev-D-Web.pdf. Products. American Diabetes Association. Accessed February 20, 2023. https://consumerguide.diabetes.org/ Wood A, O'Neal D, Furler J, Ekinci EI. Continuous glucose monitoring: a review of the evidence, opportunities for future use and ongoing challenges. Intern Med J. 2018 May;48(5):499-508. Edelman SV, Argento NB, Petty SJ, Hirsch IB. Clinical implications of real-time and intermittently scanned continuous glucose monitoring. Diabetes Care. 2018;41:2265-2274. Fonseca VA, Grunberger G, Anhalt H, et al. Continuous glucose monitoring: A consensus conference of the American Association of Clinical Endocrinologists and American College of Endocrinology. Endocr Pract. 2016;22(8):1008-21. Reiterer F, Polterauer P, Schoemaker M, Schmelzeisen-Redecker G, Freckmann G, Heinemann L, Del Re L. Significance and Reliability of MARD for the Accuracy of CGM Systems. J Diabetes Sci Technol. 2017 Jan;11(1):59-67. doi: 10.1177/1932296816662047. Epub 2016 Sep 25. PMID: 27566735; PMCID: PMC5375072. Food and Drug Administration. Premarket Notification 510(k). 2022. Accessed February 25, 2023. https://www.fda.gov/medical-devices/premarket-submissions-selecting-and-preparing-correct-submission/premarket-notification-510k. Isaacs, Diana. The pharmacist's role in continuous glucose monitoring. Pharmacy Today. 2020;26:37-54. Battelino T, Danne T, Bergenstal RM, et al. Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations from the International Consensus on Time in Range. Diabetes Care. 2019;42(8):1593-1603.